

requested sequence with Seq ID 1

Lucas 09/543,188

=> d. basis

(FILE 'REGISTRY' ENTERED AT 14:31:56 ON 02 JAN 2003)

DEL HIS Y

L1 3412 S [LWI] [LQFL] [IYVFL] [WV] I [PAFK] /SQSP
L2 32 S L1 AND SQL<21

FILE 'HCAPLUS' ENTERED AT 14:45:03 ON 02 JAN 2003

L4 24 S L2

L5 209 SEA FILE=REGISTRY ABB=ON PLU=ON GWGQPHGG/SQSP

Seq 1D 1

FILE 'HCAPLUS' ENTERED AT 14:46:49 ON 02 JAN 2003

L6 1 S L5 AND L2

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 14:47:14 ON 02 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Jan 2003 VOL 138 ISS 1
FILE LAST UPDATED: 1 Jan 2003 (20030101/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d.ca 16

L6 ANSWER 1 OF 1. HCAPLUS. COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:763326 HCAPLUS

DOCUMENT NUMBER: 135:298809

TITLE: Prion-binding ligands and methods of using same

INVENTOR(S): Hammond, David J.; Wiltshire, Vite Rose; Carbonell, Ruben; Shen, Honglue

PATENT ASSIGNEE(S): V.I Technologies, Inc., USA

SOURCE: PCT Int. Appl., 47 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077687	A2	20011018	WO 2001-US11150	20010405
WO 2001077687	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN.. INFO.: US 2000-543188 A2 20000405

OTHER SOURCE(S): MARPAT 135:298809

AB Disclosed are ligands that bind to regions of the prion peptide and methods of using same for detecting and isolating prion protein and for diagnosis and treatment of prion diseases. Also disclosed are methods for screening libraries for ligands to prions and for removal of prion protein from a biol. or environmental sample.

IC ICM G01N033-68

CC 1-11 (Pharmacology)

Section cross-reference(s): 9, 15, 17, 19

IT 366455-93-8 366455-94-9 366455-95-0

366455-96-1 366455-97-2 366455-98-3 366455-99-4 366456-00-0

366456-01-1 366456-02-2 366456-03-3 366456-04-4

366456-05-5 366456-07-7 366456-08-8 366456-09-9 366456-11-3

366456-13-5 366456-14-6 366456-15-7 366456-17-9

366456-19-1 366456-20-4 366456-22-6 366456-24-8

366456-26-0 366456-28-2 366456-30-6 366456-32-8

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(as prion ligand; prion-binding ligands and methods of using same for detecting and isolating prion proteins and for diagnosis and treatment of prion diseases)

IT 366455-92-7

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(prion proteins contg.; prion-binding ligands and methods of using same for detecting and isolating prion proteins and for diagnosis and treatment of prion diseases)

=> selec rn-hit 16 1
E1 THROUGH E8 ASSIGNED

>> fil reg

FILE "REGISTRY" ENTERED AT 14:47:31 ON 02 JAN 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JAN 2003 HIGHEST RN 477930-11-3

=> fil reg
FILE "REGISTRY" ENTERED AT 14:37:26 ON 02 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 1 JAN 2003 HIGHEST RN 477930-11-3
DICTIONARY FILE UPDATES: 1 JAN 2003 HIGHEST RN 477930-11-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d que 12
L1 3412 SEA FILE=REGISTRY ABB=ON PLU=ON [LWI] [LQFL] [IYVFL] [WV] I [PAFK]
] /SQSP
L2 32 SEA FILE=REGISTRY ABB=ON PLU=ON L1 AND SQL<21

=> d sqide3 12 1-32

L2 ANSWER 1 OF 32 REGISTRY COPYRIGHT 2003 ACS
RN 474885-61-5 REGISTRY
CN L-Serine, L-valyl-L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl-L-valyl-L-
isoleucyl-L-lysyl-L-seryl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 10

SEQ3 1 Val-Phe-Leu-Leu-Leu-Val-Ile-Lys-Ser-Ser
=====


HITS AT: -3-8

MF C55 H95 N11 O13
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

seq X₁ - X₆

↳ seq limited
to <21 residues



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 2 OF 32 REGISTRY COPYRIGHT 2003 ACS
RN 474840-27-2 REGISTRY
CN L-Serine, L-valyl-L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl-L-valyl-L-isoleucyl-L-lysyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 9

SEQ3 1 Val-Phe-Leu-Leu-Val-Ile-Lys-Ser
=====



HITS AT: 3-8

MF C52 H90 N10 O11
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



Absolute stereochemistry

Lucas 09/543, 188


PAGE 1-A



PAGE 2-A



PAGE 3-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 3 OF 32 REGISTRY COPYRIGHT 2003 ACS
 RN 474795-65-8 REGISTRY
 CN L-Serine, L-isoleucyl-L-leucyl-L-leucyl-L-valyl-L-isoleucyl-L-lysyl-L-seryl-L-seryl-L-prolyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 10


SEQ3 1 Ile-Leu-Leu-Val-Ile-Lys-Ser-Ser-Pro-Ser
 === === === === === ===

HITS AT: 1-6

MF C49 H89 N11 O14
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

OH

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 4 OF 32 REGISTRY COPYRIGHT 2003 ACS
 RN 474752-61-9 REGISTRY
 CN L-Proline, L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl-L-valyl-L-isoleucyl-L-lysyl-L-seryl-L-seryl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 10


SEQ3 1 Phe-Leu-Leu-Val-Ile-Lys-Ser-Ser-Pro
 =====

HITS AT: 2-7


MF C55 H93 N11 O13
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)

2 RÉFÉRENCES EN FICHIER CAPLUS (1962 À PRÉSENT)

L2 ANSWER 5 OF 32 REGISTRY COPYRIGHT 2003 ACS
RN 474752-48-2 REGISTRY
CN L-Serine, L-leucyl-L-leucyl-L-leucyl-L-valyl-L-isoleucyl-L-lysyl-L-seryl-L-seryl-L-prolyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 10

SEQ3 1 Leu-Leu-Leu-Val-Ile-Lys-Ser-Ser-Pro-Ser
=====

HITS AT: 1-6


MF C49 H89 N11 O14

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OH

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 6 OF 32 REGISTRY COPYRIGHT 2003 ACS
 RN 474290-33-0 REGISTRY
 CN L-Proline, L-leucyl-L-leucyl-L-leucyl-L-valyl-L-isoleucyl-L-lysyl-L-seryl-L-seryl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 9

SEQ3 1 Leu-Leu-Leu-Val-Ile-Lys-Ser-Ser-Pro
=====


HITS AT: 1-6

MF C46 H84 N10 O12

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 7 OF 32 REGISTRY COPYRIGHT 2003 ACS

RN 474289-56-0 REGISTRY

CN L-Serine, L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl-L-valyl-L-isoleucyl-L-lysyl-L-seryl- (9CI) (CA INDEX NAME)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 9

SEQ3 1 Phe-Leu-Leu-Val-Ile-Lys-Ser-Ser
=====


HITS AT: 2-7

MF C50 H86 N10 O12

SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 8 OF 32 REGISTRY COPYRIGHT 2003 ACS
RN 473787-36-9 REGISTRY
CN L-Lysine, L-glutaminyl-L-prolyl-L-valyl-L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl-L-valyl-L-isoleucyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 10

SEQ3 1 Gln-Pro-Val-Phe-Leu-Leu-Leu-Val-Ile-Lys
=====

HITS AT: 5-10


MF C59 H100 N12 O12

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

4 REFERENCES IN FILE CA (1962 TO DATE)
 4 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 9 OF 32 REGISTRY COPYRIGHT 2003 ACS
 RN 473454-04-5 REGISTRY
 CN L-Asparagine, L-glutaminyl-L-prolyl-L-valyl-L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl-L-valyl-L-isoleucyl-L-lysyl-L-seryl-L-seryl-L-prolyl-L-seryl-(9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 15


SEQ3 1 Gln-Pro-Val-Phe-Leu-Leu-Val-Ile-Lys-
 =====
 11 Ser-Ser-Pro-Ser-Asn

HITS AT: 5-10


MF C77 H128 N18 O21
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L2 ANSWER 10 OF 32 REGISTRY COPYRIGHT 2003 ACS
 RN 473453-98-4 REGISTRY
 CN L-Valine, L-valyl-L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl-L-valyl-L-isoleucyl-L-lysyl-L-seryl-L-seryl-L-prolyl-L-seryl-L-asparaginyl-L-tyrosyl-(9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSearch
 SQL 15

SEQ3 1 Val-Phe-Leu-Leu-Val-Ile-Lys-Ser-Ser-
 =====
 11 Pro-Ser-Asn-Tyr-Val
 HITS AT: 3-8


MF C81 H131 N17 O21
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 2-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L2 ANSWER 11 OF 32 REGISTRY COPYRIGHT 2003 ACS
 RN 473453-97-3 REGISTRY
 CN L-Serine, L-alanyl-L-glutaminyl-L-prolyl-L-valyl-L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl-L-valyl-L-isoleucyl-L-lysyl-L-seryl-L-seryl-L-prolyl-(9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 15

SEQ3 1 Ala-Gln-Pro-Val-Phe-Leu-Leu-Leu-Val-Ile-
 =====
 11 Lys-Ser-Ser-Pro-Ser
 =====
 HITS AT: 6-11


MF C76 H127 N17 O20
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1962 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 12 OF 32. REGISTRY COPYRIGHT 2003 ACS
 RN 473453-49-5 REGISTRY
 CN L-Arginine, L-leucyl-L-leucyl-L-leucyl-L-valyl-L-isoleucyl-L-lysyl-L-seryl-L-seryl-L-prolyl-L-seryl-L-asparaginyl-L-tyrosyl-L-valyl-L-arginyl- (9CI)
 (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 15

SEQ3 ... 1 Leu-Leu-Leu-Val-Ile-Lys-Ser-Ser-Pro-Ser-...
 ======
 11 Asn-Tyr-Val-Arg-Arg

HITS AT: 1-6


MF C79 H137 N23 O21
 SR CA

Lucas 09/543, 188


LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 13 OF 32 REGISTRY COPYRIGHT 2003 ACS
 RN 473453-08-6 REGISTRY
 CN L-Arginine, L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl-L-valyl-L-isoleucyl-L-lysyl-L-seryl-L-seryl-L-prolyl-L-seryl-L-asparaginyl-L-tyrosyl-L-valyl-(9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 15


SEQ3 1 Phe-Leu-Leu-Val-Ile-Lys-Ser-Ser-Pro-
 === === === === ===
 11 Ser-Asn-Tyr-Val-Arg
 HITS AT: 2-7

MF C82 H134 N20 O21
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER



Absolute stereochemistry.

Lucas 09/543,188


PAGE 1-A



PAGE 2-A



PAGE 2-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 14 OF 32 REGISTRY COPYRIGHT 2003 ACS
RN 473452-76-5 REGISTRY
CN L-Tyrosine, L-prolyl-L-valyl-L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl-L-
valyl-L-isoleucyl-L-lysyl-L-seryl-L-seryl-L-prolyl-L-seryl-L-asparaginyl-
(9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 15

```

SEQ3      1 Pro-Val-Phe-Leu-Leu-Val-Ile-Lys-Ser-
                  === === === === === === ===
                  11 Ser-Pro-Ser-Asn-Tyr

```

HITS AT: 4-9


MF C81 H129 N17 O21

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L2 ANSWER 15 OF 32 REGISTRY COPYRIGHT 2003 ACS
 RN 473326-01-1 REGISTRY
 CN L-Lysine, L-prolyl-L-valyl-L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl-L-isoleucyl-L-valyl-L-prolyl-L-lysine (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 9

SEQ3 1 Pro-Val-Phe-Leu-Leu-Val-Ile-Lys
 =====

HITS AT: 4-9

MF C54 H92 N10 O10
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3 REFERENCES IN FILE CA (1962 TO DATE)
 3 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 16 OF 32 REGISTRY COPYRIGHT 2003 ACS

RN 444319-65-7 REGISTRY

CN L-Alanine, L-methionyl-L-lysylglycyl-L-tryptophyl-L-leucyl-L-phenylalanyl-L-leucyl-L-valyl-L-isoleucyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Quaternary ammonium compound-resistance protein (Acinetobacter strain YMCU160 gene qacEdelta1)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 10

SEQ3 1 Met-Lys-Gly-Trp-Leu-Phe-Leu-Val-Ile-Ala
 =====

HITS AT: 5-10


MF C59 H92 N12 O11 S

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

Et

PAGE 2-A

HO₂C Me

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 17 OF 32 REGISTRY COPYRIGHT 2003 ACS
 RN 413565-92-1 REGISTRY
 CN L-Lysine, L-asparaginyl-L-seryl-L-leucyl-L-leucyl-L-glutaminyl-L-isoleucyl-L-valyl-L-isoleucyl-L-prolyl-L-.alpha.-glutamyl- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 16: PN: WO0232939 PAGE: 20 unclaimed sequence
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 11

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
=====+=====	
Not Given	WO2002032939
	unclaimed
	PAGE 20

SEQ3 1 Asn-Ser-Leu-Leu-Gln-Ile-Val-Ile-Pro-Glu-
 ======


11 Lys

HITS AT: 4-9


MF C57 H100 N14 O17
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 18 OF 32 REGISTRY COPYRIGHT 2003 ACS
 RN 366456-26-0 REGISTRY
 CN L-Alanine, L-tryptophyl-L-leucyl-L-valyl-L-tryptophyl-L-isoleucyl- (9CI)
 (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 6

SEQ3 1 Trp-Leu-Val-Trp-Ile-Ala
 =====

HITS AT: 1-6


MF C42 H58 N8 O7


SR CA

LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L2 ANSWER 19 OF 32 REGISTRY COPYRIGHT 2003 ACS
RN 366456-19-1 REGISTRY
CN L-Lysine, L-isoleucyl-L-phenylalanyl-L-phenylalanyl-L-tryptophyl-L-isoleucyl- (9CI) (CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 6

SEQ3 1 Ile-Phe-Phe-Trp-Ile-Lys
=====

HITS AT: 1-6

MF C47 H64 N8 O7
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L2 ANSWER 20 OF 32 REGISTRY COPYRIGHT 2003 ACS
 RN 366456-15-7 REGISTRY
 CN L-Phenylalanine, L-isoleucyl-L-glutaminyl-L-isoleucyl-L-tryptophyl-L-isoleucyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 6

SEQ3 1 Ile-Gln-Ile-Trp-Ile-Phe
 === === === === === ===

HITS AT: 1-6

MF C43 H62 N8 O8
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L2 ANSWER 21 OF 32 REGISTRY COPYRIGHT 2003 ACS
 RN 366456-04-4 REGISTRY
 CN L-Alanine, L-leucyl-L-leucyl-L-leucyl-L-valyl-L-isoleucyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 6

SEQ3 1 Leu-Leu-Leu-Val-Ile-Ala
 =====

HITS AT: 1-6

MF C32 H60 N6 O7
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 22 OF 32 REGISTRY COPYRIGHT 2003 ACS
RN 366455-95-0 REGISTRY
CN L-Proline, L-tryptophyl-L-leucyl-L-tyrosyl-L-tryptophyl-L-isoleucyl- (9CI)
(CA INDEX NAME)
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 6

SEQ3 1 Trp-Leu-Tyr-Trp-Ile-Pro
=====

HITS AT: 1-6


MF C48 H60 N8 O8

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)


L2 ANSWER 23 OF 32 REGISTRY COPYRIGHT 2003 ACS
 RN 366455-94-9 REGISTRY
 CN L-Proline, L-leucyl-L-leucyl-L-isoleucyl-L-tryptophyl-L-isoleucyl- (9CI)
 (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 6

SEQ3 1 Leu-Leu-Ile-Trp-Ile-Pro
 === === === === === ===

HITS AT: 1-6

MF C40 H63 N7 O7
 SR CA
 LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 24 OF 32 REGISTRY COPYRIGHT 2003 ACS
RN 364319-27-7 REGISTRY
CN L-Glutamine, L-methionyl-L-threonyl-L-isoleucyl-L-leucyl-L-leucyl-L-
isoleucyl-L-valyl-L-isoleucyl-L-prolyl-L-valyl-L-leucyl-L-valyl-L-valyl-
(9CI) (CA INDEX NAME)
OTHER NAMES:
CN 72: PN: WO0147944 SEQID: 7939 claimed sequence
FS PROTEIN SEQUENCE; STEREOSEARCH
SOL 14

PATENT ANNOTATIONS (PNTE) :

Sequence Source	Patent Reference
Not Given	WO2001047944 claimed SEQID 7939

SEQ3 1 Met-Thr-Ile-Leu-Leu-Ile-Val-Ile-Pro-Val-
 ==== == == == == == == == == == == ==
11 Leu-Val-Val-Gln

HITS AT: 4-9


MF C75 H135 N15 O17 S

SR CA



LC STN Files: CA, CAPIUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A





PAGE 2-A




PAGE 2-B

-NH₂

PAGE 3-A



PAGE 4-A



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 25 OF 32 REGISTRY COPYRIGHT 2003 ACS

RN 345316-07-6 REGISTRY

CN Glycine, L-tryptophyl-L-methionyl-L-isoleucyl-L-phenylalanyl-L-valyl-L-valyl-L-isoleucyl-L-alanyl-L-seryl-L-valyl-L-phenylalanyl-L-threonyl-L-asparaginyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 271: PN: WO0148245 SEQID: 800 claimed protein

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 14

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference

Not Given	WO2001048245
	claimed
	SEQID 800

SEQ3 1 Trp-Met-Ile-Phe-Val-Val-Ile-Ala-Ser-Val-

11 Phe-Thr-Asn-Gly

HITS AT: 3-8


MF C77 H114 N16 O18 S

SR CA


LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 26 OF 32 REGISTRY COPYRIGHT 2003 ACS

RN 344842-59-7 REGISTRY

CN L-Alanine, L-leucyl-L-leucyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-valyl-L-isoleucyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1258: PN: WO0142277 SEQID: 1277 unclaimed sequence

FS PROTEIN SEQUENCE; STEREORESEARCH

SQL 10

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
<hr/>	
Not Given	WO2001042277
	unclaimed
	SEQID 1277

SEQ3 1 Leu-Leu-Phe-Leu-Phe-Ile-Val-Ile-Phe-Ala
 =====


HITS AT: 4-9

MF C65 H98 N10 O11

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 27 OF 32 REGISTRY COPYRIGHT 2003 ACS

RN 344842-57-5 REGISTRY

CN L-Phenylalanine, L-leucyl-L-leucyl-L-leucyl-L-phenylalanyl-L-leucyl-L-phenylalanyl-L-isoleucyl-L-valyl-L-isoleucyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 1256: PN: WO0142277 SEQID: 1275 unclaimed sequence

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 10

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
----------	--------

Source	Reference
--------	-----------

=====+=====

Not Given	WO2001042277
-----------	--------------

	unclaimed
--	-----------

	SEQID 1275
--	------------

SEQ3 1 Leu-Leu-Leu-Phe-Leu-Phe-Ile-Val-Ile-Phe

==== == == == == == ==

HITS AT: 5-10


MF C68 H104 N10 O11

SR CA

LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 28 OF 32 REGISTRY COPYRIGHT 2003 ACS
 RN 295789-26-3 REGISTRY
 CN L-Leucine, L-methionyl-L-lysyl-L-leucyl-L-leucyl-L-isoleucyl-L-valyl-L-isoleucyl-L-phenylalanyl-L-phenylalanyl-L-histidyl-L-phenylalanyl- (9CI)
 (CA INDEX NAME)
 OTHER NAMES:
 CN 120: PN: WO0058335 SEQID: 63 claimed sequence
 CN Secretory peptide (human clone HMQCL80 precursor)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 12

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	=====
	WO2000058335
	claimed
	SEQID 63


SEQ3 1 Met-Lys-Leu-Leu-Ile-Val-Ile-Phe-Phe-His-

=====


11 Phe-Leu
HITS AT: 3-8MF C79 H121 N15 O13 S
SR CA
LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 29 OF 32 REGISTRY COPYRIGHT 2003 ACS
 RN 273407-82-2 REGISTRY
 CN L-Proline, L-leucyl-L-seryl-L-alanyl-L-methionyl-L-leucylglycyl-L-alanyl-L-leucyl-L-phenylalanyl-L-leucyl-L-tryptophyl-L-isoleucyl-L-phenylalanyl-L-tryptophyl- (9CI) (CA INDEX NAME)
 OTHER NAMES:
 CN 349: PN: WO0032785 SEQID: 87 claimed sequence

FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 15

PATENT ANNOTATIONS (PNTE) :

Sequence	Patent
Source	Reference
=====+=====	
Not Given	WO2000032785
	claimed
	SEQID 87

SEQ3 1 Leu-Ser-Ala-Met-Leu-Gly-Ala-Leu-Phe-Leu-
=====

11 Trp-Ile-Phe-Trp-Pro

====

HITS AT: 8-13


MF C91 H129 N17 O17 S

SR CA


LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



PAGE 2-A



PAGE 2-B



1 REFERENCES IN FILE CA (1962 TO DATE)
1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 30 OF 32 REGISTRY COPYRIGHT 2003 ACS

RN 197582-80-2 REGISTRY

CN L-Alanine, glycyl-L-alanyl-L-leucyl-L-phenylalanyl-L-leucyl-L-tryptophyl-L-isoleucyl-L-phenylalanyl-L-tryptophyl-L-prolyl-L-seryl-L-phenylalanyl-L-asparaginyl-L-seryl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 321: PN: WO0032785 SEQID: 59 claimed sequence

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 15

PATENT ANNOTATIONS (PNTE) :

Sequence	Patent
Source	Reference
Not Given	WO200003278
	claimed
	SEQID 59

```

SEQ3      1 Gly-Ala-Leu-Phe-Leu-Trp-Ile-Phe-Trp-Pro-
                  === === === === === === ===
          11 Ser-Phe-Asn-Ser-Ala


```

HITS AT: 3 - 8


MF C90 H118 N18 O19
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



2 REFERENCES IN FILE CA (1962 TO DATE)
 2 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 31 OF 32 REGISTRY COPYRIGHT 2003 ACS

RN 157414-63-6 REGISTRY

CN L-Serine, L-methionyl-L-lysyl-L-leucyl-L-prolyl-L-valyl-L-arginyl-L-leucyl-L-leucyl-L-valyl-L-leucyl-L-leucyl-L-phenylalanyl-L-tryptophyl-L-isoleucyl-L-prolyl-L-alanyl-L-seryl-L-isoleucyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Humanized antibody Br-E3 to human milk fat globule analog light chain variable region fragment (mouse human clone 152)

FS PROTEIN SEQUENCE; STEREOSEARCH

SQL 19

SEQ3 1 Met-Lys-Leu-Pro-Val-Arg-Leu-Leu-Val-Leu-

====

11 Leu-Phe-Trp-Ile-Pro-Ala-Ser-Ile-Ser

HITS AT: 10-15


MF C108 H178 N24 O22 S

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-C



1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

L2 ANSWER 32 OF 32. REGISTRY COPYRIGHT 2003 ACS
 RN 76877-09-3 REGISTRY
 CN Glycine, L-methionyl-L-valyl-L-seryl-L-threonyl-L-prolyl-L-glutaminyl-L-phenylalanyl-L-leucyl-L-valyl-L-phenylalanyl-L-leucyl-L-leucyl-L-phenylalanyl-L-tryptophyl-L-isoleucyl-L-prolyl- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 17


SEQ3 1 Met-Val-Ser-Thr-Pro-Gln-Phe-Leu-Val-Phe-
 11 Leu-Leu-Phe-Trp-Ile-Pro-Gly
 === === === === === ===

HITS AT: 11-16


MF C101 H147 N19 O21 S
 LC STN Files: CA, CAPLUS

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C

— SMe

1 REFERENCES IN FILE CA (1962 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1962 TO DATE)

=> fil hcaplus
FILE 'HCAPLUS' ENTERED AT 14:45:14 ON 02 JAN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 2 Jan 2003 VOL 138 ISS 1
FILE LAST UPDATED: 1 Jan 2003 (20030101/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.
'OBI' IS DEFAULT SEARCH FIELD FOR 'HCAPLUS' FILE

=> d his 14

L4 24 S L2

=> d .ca 14 1-24

L4 ANSWER 1 OF 24 HCAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:857454 HCAPLUS
DOCUMENT NUMBER: 137:380983
TITLE: Human nucleic acids and corresponding proteins useful
in the detection and treatment of various cancers
INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;
Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
Morrison, Robert Kendall; Raitano, Arthur B.
PATENT ASSIGNEE(S): Agensys, Inc., USA
SOURCE: PCT Int. Appl., 1021 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 25
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XM11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 WO 2002083921 A2 20021024 WO 2002-US11654 20020410
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
 US 2001-283112P P 20010410
 US 2001-286630P P 20010425
 WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.] .

ICI C12

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 9, 14

IT	473786-66-2	473786-67-3	473786-68-4	473786-69-5	473786-70-8
	473786-71-9	473786-76-4	473786-78-6	473786-80-0	473786-84-4
	473786-85-5	473786-86-6	473786-88-8	473786-90-2	473786-92-4
	473786-94-6	473787-13-2	473787-24-5	473787-27-8	473787-32-5
	473787-36-9	473787-49-4	473787-51-8	473787-58-5	
	473787-60-9	473787-61-0	473787-62-1	473787-65-4	473787-67-6
	473787-82-5	473787-88-1	473787-89-2	473788-03-3	473788-07-7
	473788-12-4	473788-13-5	473788-21-5	473788-29-3	473788-50-0
	473788-52-2	473788-85-1	473789-02-5	473789-25-2	473789-42-3
	473789-77-4	473790-17-9	473790-20-4	473790-30-6	473790-40-8
	473790-50-0	473790-57-7	473790-92-0	473791-01-4	473791-03-6
	473791-13-8	473791-33-2	473791-53-6	473791-57-0	473791-65-0
	473791-78-5	473791-82-1	473791-94-5	473791-97-8	473792-00-6
	473792-03-9	473792-08-4	473792-11-9	473792-19-7	473792-28-8
	473792-35-7	473792-39-1	473792-40-4	473792-52-8	473792-56-2
	473792-59-5	473792-74-4	473792-96-0	473793-02-1	473793-03-2
	473793-07-6	473793-09-8	473793-39-4	473793-55-4	473793-58-7
	473793-60-1	473793-64-5	473793-70-3	473793-72-5	473793-73-6
	473793-76-9	473793-82-7	473793-93-0	473793-94-1	473793-95-2
	473793-96-3	473793-99-6	473794-00-2	473794-04-6	473794-13-7
	473794-14-8	473794-17-1	473794-19-3	473794-25-1	473794-28-4

473794-29-5	473794-40-0	473794-43-3	473794-49-9	473794-50-2
473794-54-6	473794-56-8	473794-58-0	473794-66-0	473794-67-1
473794-68-2	473794-72-8	473794-74-0	473794-75-1	473794-77-3
474291-05-9	474746-17-3	474746-18-4	474746-19-5	474746-20-8
474746-21-9	474746-22-0	474746-24-2	474746-25-3	474746-27-5
474746-28-6	474746-29-7	474746-30-0	474746-33-3	474746-34-4
474746-35-5	474746-36-6	474746-37-7	474746-38-8	474746-41-3
474746-43-5	474746-44-6	474746-46-8	474746-47-9	474746-48-0
474746-50-4	474746-51-5	474746-52-6	474746-53-7	474746-54-8
474746-55-9	474746-56-0	474746-57-1	474746-58-2	474746-59-3
474746-61-7	474746-62-8	474746-63-9	474746-68-4	474746-75-3
474746-77-5	474746-82-2	474746-83-3	474746-85-5	474746-87-7
474746-88-8	474746-93-5	474747-02-9	474747-05-2	474747-09-6
474747-12-1	474747-14-3	474747-18-7	474747-26-7	474747-41-6
474747-42-7	474747-44-9	474747-49-4	474747-50-7	474747-51-8
474747-60-9	474747-64-3	474747-65-4	474747-66-5	474747-67-6
474747-70-1	474747-73-4	474747-86-9	474747-89-2	474747-94-9
474747-97-2	474748-01-1	474748-14-6	474748-16-8	474748-31-7
474748-40-8	474748-48-6	474748-56-6	474748-61-3	474748-71-5
474748-72-6	474748-76-0	474748-79-3	474748-80-6	474748-84-0
474748-87-3	474748-88-4	474748-89-5	474748-91-9	474748-92-0
474748-93-1	474748-94-2	474748-95-3	474748-96-4	474748-97-5
474748-98-6	474748-99-7	474749-00-3	474749-02-5	474749-03-6
474749-04-7	474749-05-8	474749-06-9	474749-07-0	474749-08-1
474749-11-6	474749-12-7	474749-13-8	474749-16-1	474749-17-2
474749-18-3	474749-19-4	474749-20-7	474749-21-8	

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope) human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L4 ANSWER 2 OF 24 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:857452 HCAPLUS
 DOCUMENT NUMBER: 137:380981
 TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 25
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XK11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

WO 2002083921 A2 20021024 WO 2002-US11654 20020410
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-282739P P 20010410
 US 2001-283112P P 20010410
 US 2001-286630P P 20010425

WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

ICI C12

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 9, 14

IT	474883-43-7	474883-44-8	474883-45-9	474883-46-0	474883-47-1
	474883-48-2	474883-49-3	474883-50-6	474883-51-7	474883-52-8
	474883-53-9	474883-54-0	474883-55-1	474883-56-2	474883-57-3
	474883-58-4	474883-59-5	474883-60-8	474883-61-9	474883-62-0
	474883-63-1	474883-64-2	474883-65-3	474883-66-4	474883-67-5
	474883-68-6	474883-69-7	474883-70-0	474883-71-1	474883-72-2
	474883-73-3	474883-74-4	474883-75-5	474883-76-6	474883-77-7
	474883-78-8	474883-79-9	474883-80-2	474883-81-3	474883-82-4
	474883-83-5	474883-84-6	474883-85-7	474883-86-8	474883-87-9
	474883-88-0	474883-89-1	474883-90-4	474883-91-5	474883-92-6
	474883-93-7	474883-94-8	474883-95-9	474883-96-0	474883-97-1
	474883-98-2	474883-99-3	474884-00-9	474884-01-0	474884-02-1
	474884-03-2	474884-04-3	474884-05-4	474884-06-5	474884-07-6
	474884-08-7	474884-09-8	474884-10-1	474884-11-2	474884-12-3
	474884-13-4	474884-14-5	474884-15-6	474884-16-7	474884-17-8
	474884-18-9	474884-19-0	474884-20-3	474884-22-5	474884-24-7
	474884-28-1	474884-32-7	474884-39-4	474884-40-7	474884-41-8
	474884-53-2	474884-60-1	474884-61-2	474884-62-3	474884-63-4
	474884-64-5	474884-65-6	474884-66-7	474884-67-8	474884-68-9
	474884-69-0	474884-70-3	474884-71-4	474884-72-5	474884-73-6
	474884-74-7	474884-75-8	474884-76-9	474884-77-0	474884-78-1
	474884-79-2	474884-80-5	474884-81-6	474884-82-7	474884-83-8
	474884-84-9	474884-85-0	474884-86-1	474884-87-2	474884-88-3
	474884-89-4	474884-90-7	474884-91-8	474884-93-0	474884-94-1
	474884-95-2	474884-96-3	474884-97-4	474885-01-3	474885-02-4
	474885-13-7	474885-14-8	474885-15-9	474885-16-0	474885-17-1
	474885-18-2	474885-19-3	474885-20-6	474885-21-7	474885-22-8
	474885-23-9	474885-24-0	474885-25-1	474885-26-2	474885-27-3
	474885-28-4	474885-29-5	474885-30-8	474885-31-9	474885-32-0

474885-33-1	474885-34-2	474885-35-3	474885-36-4	474885-37-5
474885-38-6	474885-39-7	474885-40-0	474885-41-1	474885-42-2
474885-43-3	474885-44-4	474885-45-5	474885-46-6	474885-47-7
474885-48-8	474885-49-9	474885-50-2	474885-51-3	474885-52-4
474885-53-5	474885-54-6	474885-55-7	474885-56-8	474885-57-9
474885-58-0	474885-59-1	474885-60-4	474885-61-5	
474885-62-6	474885-63-7	474885-64-8	474885-65-9	474885-66-0
474885-67-1	474885-68-2	474885-69-3	474885-70-6	474885-71-7
474885-72-8	474885-73-9	474885-74-0	474885-75-1	474885-76-2
474885-77-3	474885-78-4	474885-79-5	474885-80-8	474885-81-9
474885-82-0	474885-83-1	474885-84-2	474885-85-3	474885-86-4
474885-87-5	474885-88-6	474885-89-7	474885-90-0	474885-91-1
474885-92-2	474885-93-3	474885-94-4	474885-95-5	474885-96-6
474885-97-7	474885-98-8	474885-99-9	474886-00-5	474886-01-6
474886-02-7	474886-03-8	474886-04-9	474886-05-0	474886-06-1
474886-07-2	474886-08-3	474886-09-4	474886-10-7	474886-11-8
474886-12-9	474886-13-0	474886-14-1	474886-15-2	474886-16-3
474886-17-4	474886-18-5	474886-19-6	474886-20-9	

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L4 ANSWER 3 OF 24 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:857451 HCPLUS

DOCUMENT NUMBER: 137:380980

TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers

INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.

PATENT ASSIGNEE(S): Agensys, Inc., USA

SOURCE: PCT Int. Appl., 1021 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 25

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XJ11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				

CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
 US 2001-283112P P 20010410
 US 2001-286630P P 20010425
 WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

ICI C12

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 9, 14

IT	474836-54-9	474836-56-1	474836-59-4	474836-60-7	474836-62-9
	474836-63-0	474836-64-1	474836-66-3	474836-69-6	474836-70-9
	474836-71-0	474836-72-1	474836-74-3	474836-75-4	474836-77-6
	474836-79-8	474836-80-1	474836-82-3	474836-83-4	474836-85-6
	474836-87-8	474836-88-9	474836-91-4	474836-92-5	474836-93-6
	474836-95-8	474836-96-9	474836-97-0	474836-98-1	474836-99-2
	474837-00-8	474837-01-9	474837-02-0	474837-04-2	474837-05-3
	474837-06-4	474837-08-6	474837-09-7	474837-13-3	474837-14-4
	474837-24-6	474837-29-1	474837-30-4	474837-31-5	474837-33-7
	474837-34-8	474837-36-0	474837-37-1	474837-42-8	474837-43-9
	474837-46-2	474837-52-0	474837-53-1	474837-54-2	474837-56-4
	474837-61-1	474837-62-2	474837-63-3	474837-98-4	474838-00-1
	474838-01-2	474838-02-3	474838-03-4	474838-04-5	474838-05-6
	474838-07-8	474838-08-9	474838-09-0	474838-10-3	474838-14-7
	474838-16-9	474838-19-2	474838-21-6	474838-23-8	474838-25-0
	474838-27-2	474838-28-3	474838-30-7	474838-34-1	474838-51-2
	474838-53-4	474838-55-6	474838-57-8	474838-60-3	474838-61-4
	474838-62-5	474838-63-6	474838-64-7	474838-65-8	474838-66-9
	474838-67-0	474838-68-1	474838-69-2	474838-71-6	474838-72-7
	474838-74-9	474838-77-2	474838-78-3	474838-79-4	474838-80-7
	474838-81-8	474838-85-2	474838-86-3	474838-87-4	474838-88-5
	474838-89-6	474838-90-9	474838-91-0	474838-94-3	474838-96-5
	474838-98-7	474839-00-4	474839-04-8	474839-05-9	474839-07-1
	474839-08-2	474839-09-3	474839-10-6	474839-11-7	474839-14-0
	474839-20-8	474839-22-0	474839-28-6	474839-31-1	474839-46-8
	474839-49-1	474839-50-4	474839-51-5	474839-52-6	474839-54-8
	474839-55-9	474839-58-2	474839-61-7	474839-62-8	474839-65-1
	474839-66-2	474839-68-4	474839-70-8	474839-72-0	474839-74-2
	474839-75-3	474839-77-5	474839-79-7	474839-85-5	474839-86-6
	474839-87-7	474839-88-8	474839-89-9	474839-90-2	474839-92-4
	474839-94-6	474839-95-7	474839-96-8	474839-97-9	474839-98-0
	474839-99-1	474840-01-2	474840-02-3	474840-04-5	474840-05-6
	474840-06-7	474840-07-8	474840-09-0	474840-12-5	474840-13-6
	474840-14-7	474840-15-8	474840-16-9	474840-23-8	474840-24-9
	474840-25-0	474840-27-2	474840-28-3	474840-30-7	
	474840-32-9	474840-33-0	474840-34-1	474840-36-3	474840-37-4
	474840-38-5	474840-40-9	474840-41-0	474840-42-1	474840-43-2

474840-44-3	474840-45-4	474840-46-5	474840-47-6	474840-48-7
474840-49-8	474840-50-1	474840-51-2	474840-52-3	474840-53-4
474840-54-5	474840-55-6	474840-56-7	474840-57-8	474840-58-9
474840-59-0	474840-61-4	474840-62-5	474840-63-6	474840-64-7
474840-65-8	474840-69-2	474840-70-5	474840-71-6	474840-73-8
474840-74-9	474840-78-3	474840-79-4	474840-80-7	474840-81-8
474840-82-9	474840-84-1	474840-86-3	474840-87-4	474840-91-0
474840-92-1	474840-95-4	474840-96-5	474840-97-6	474840-98-7
474840-99-8	474841-00-4	474841-01-5	474841-02-6	474841-03-7
474841-04-8	474841-05-9	474841-06-0	474841-07-1	

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L4 ANSWER 4 OF 24 HCPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:857450 HCPLUS
DOCUMENT NUMBER: 137:380979
TITLE: Human nucleic acids and corresponding proteins useful
in the detection and treatment of various cancers
INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;
Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
Morrison, Robert Kendall; Raitano, Arthur B.
PATENT ASSIGNEE(S): Agensys, Inc.; USA
SOURCE: PCT Int. Appl., 1021 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 25
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XI11654	20020410
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
IRITY APPLN. INFO.:			US 2001-282739P	P 20010410
			US 2001-283112P	P 20010410
			US 2001-286630P	P 20010425
			WO 2002-US11654	A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult

tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.]

ICI	C12			
CC	3-3 (Biochemical Genetics)			
Section cross-reference(s): 1, 6, 9, 14				
IT				
473784-32-6	473784-33-7	473784-34-8	473784-35-9	473784-36-0
473784-37-1	473784-38-2	473784-39-3	473784-40-6	473784-41-7
473784-42-8	473784-43-9	473784-44-0	473784-45-1	473784-46-2
473784-54-2	473784-55-3	473784-56-4	473784-60-0	473784-61-1
473784-62-2	473784-63-3	473784-68-8	473784-72-4	473784-74-6
473784-76-8	473784-77-9	473784-78-0	473784-80-4	473784-81-5
473784-82-6	473784-83-7	473784-85-9	473784-86-0	473784-87-1
473784-89-3	473784-90-6	473784-91-7	473784-93-9	473784-94-0
473784-95-1	473784-96-2	473784-98-4	473784-99-5	473785-00-1
473785-01-2	473785-02-3	473785-03-4	473785-04-5	473785-07-8
473785-08-9	473785-10-3	473785-12-5	473785-13-6	473785-14-7
473785-15-8	473785-16-9	473785-17-0	473785-18-1	473785-19-2
473785-20-5	473785-21-6	473785-23-8	473785-24-9	473785-25-0
473785-26-1	473785-27-2	473785-28-3	473785-29-4	473785-30-7
473785-31-8	473785-37-4	473785-38-5	473785-39-6	473785-40-9
473785-41-0	473785-43-2	473785-44-3	473785-45-4	473785-46-5
473785-47-6	473785-49-8	473785-50-1	473785-51-2	473785-57-8
473785-58-9	473785-59-0	473785-62-5	473785-64-7	473785-65-8
473785-68-1	473785-70-5	473785-71-6	473785-73-8	473785-74-9
473785-75-0	473785-76-1	473785-77-2	473785-82-9	473785-83-0
473785-84-1	473785-85-2	473785-87-4	473785-90-9	473785-93-2
473785-94-3	473785-95-4	473785-96-5	473785-99-8	473786-00-4
473786-01-5	473786-02-6	473786-05-9	473786-09-3	473786-10-6
473786-12-8	473786-13-9	473786-14-0	473786-15-1	473786-16-2
473786-23-1	473786-24-2	473786-25-3	473786-27-5	473786-28-6
473786-29-7	473786-30-0	473786-34-4	473786-35-5	473786-39-9
473786-42-4	473786-43-5	473786-44-6	473786-45-7	473786-50-4
473786-51-5	473786-52-6	473786-53-7	473786-55-9	473786-59-3
473786-65-1	473786-69-5	473786-70-8	473786-71-9	473786-72-0
473786-73-1	473786-74-2	473786-76-4	473786-77-5	473786-78-6
473786-83-3	473786-85-5	473786-86-6	473786-87-7	473786-89-9
473786-90-2	473786-94-6	473786-95-7	473786-96-8	473786-97-9
473786-99-1	473787-00-7	473787-03-0	473787-08-5	473787-09-6
473787-10-9	473787-11-0	473787-12-1	473787-13-2	473787-14-3
473787-15-4	473787-16-5	473787-18-7	473787-22-3	473787-23-4
473787-25-6	473787-32-5	473787-34-7	473787-36-9	
473787-37-0	473787-38-1	473787-39-2	473787-40-5	473787-44-9
473787-49-4	473787-51-8	473787-52-9	473787-55-2	473787-58-5
473787-60-9	473787-61-0	473787-62-1	473787-63-2	473787-65-4
473787-66-5	473787-73-4	473787-75-6	473787-78-9	473787-81-4
473787-87-0	473787-90-5	473787-92-7	473787-93-8	473787-98-3
473787-99-4	473788-00-0	473788-01-1	473788-08-8	473788-12-4
473788-13-5	473788-18-0	473788-19-1	473788-20-4	473788-23-7
473788-24-8	473788-25-9	473788-26-0	473788-36-2	473788-39-5
473788-45-3	473788-51-1	473788-52-2	473788-54-4	473788-57-7

473788-58-8 473788-62-4 473788-64-6 473788-69-1 473788-80-6
 473788-81-7 473788-82-8 473788-84-0 473788-89-5
 RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L4 ANSWER 5 OF 24 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:857449 HCAPLUS
 DOCUMENT NUMBER: 137:380978
 TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 25
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XH11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2001-282739 P	20010410
			US 2001-283112 P	20010410
			US 2001-286630 P	20010425
			WO 2002-US11654 A	20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response;

antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.]

ICI C12
 CC 3-3 (Biochemical Genetics)
 Section cross-reference(s): 1, 6, 9, 14

IT	473322-36-0	473322-37-1	473322-38-2	473322-39-3	473322-41-7
	473322-42-8	473322-44-0	473322-45-1	473322-46-2	473322-48-4
	473322-49-5	473322-50-8	473322-51-9	473322-53-1	473322-54-2
	473322-55-3	473322-56-4	473322-57-5	473322-59-7	473322-60-0
	473322-61-1	473322-62-2	473322-63-3	473322-64-4	473322-65-5
	473322-66-6	473322-67-7	473322-69-9	473322-70-2	473322-71-3
	473322-73-5	473322-77-9	473322-80-4	473322-82-6	473322-83-7
	473322-85-9	473322-88-2	473322-90-6	473322-91-7	473322-92-8
	473322-95-1	473322-96-2	473322-97-3	473323-00-1	473323-01-2
	473323-03-4	473323-04-5	473323-06-7	473323-10-3	473323-11-4
	473323-12-5	473323-14-7	473323-15-8	473323-17-0	473323-18-1
	473323-19-2	473323-21-6	473323-23-8	473323-24-9	473323-25-0
	473323-26-1	473323-27-2	473323-28-3	473323-29-4	473323-30-7
	473323-31-8	473323-32-9	473323-34-1	473323-35-2	473323-36-3
	473323-37-4	473323-38-5	473323-39-6	473323-44-3	473323-45-4
	473323-46-5	473323-47-6	473323-49-8	473323-50-1	473323-51-2
	473323-57-8	473323-58-9	473323-59-0	473323-60-3	473323-62-5
	473323-63-6	473323-64-7	473323-66-9	473323-67-0	473323-68-1
	473323-69-2	473323-70-5	473323-71-6	473323-72-7	473323-73-8
	473323-74-9	473323-76-1	473323-77-2	473323-78-3	473323-79-4
	473323-81-8	473323-83-0	473323-85-2	473323-86-3	473323-88-5
	473323-89-6	473323-90-9	473323-91-0	473323-93-2	473323-94-3
	473323-95-4	473323-98-7	473324-00-4	473324-01-5	473324-05-9
	473324-06-0	473324-07-1	473324-10-6	473324-11-7	473324-13-9
	473324-14-0	473324-16-2	473324-19-5	473324-22-0	473324-25-3
	473324-27-5	473324-29-7	473324-30-0	473324-31-1	473324-34-4
	473324-35-5	473324-39-9	473324-40-2	473324-41-3	473324-42-4
	473324-43-5	473324-44-6	473324-45-7	473324-47-9	473324-51-5
	473324-53-7	473324-54-8	473324-55-9	473324-57-1	473324-58-2
	473324-59-3	473324-60-6	473324-61-7	473324-66-2	473324-67-3
	473324-68-4	473324-69-5	473324-73-1	473324-74-2	473324-75-3
	473324-76-4	473324-84-4	473324-85-5	473324-86-6	473324-90-2
	473324-91-3	473325-02-9	473325-03-0	473325-04-1	473325-06-3
	473325-07-4	473325-10-9	473325-11-0	473325-18-7	473325-19-8
	473325-20-1	473325-21-2	473325-22-3	473325-27-8	473325-28-9
	473325-31-4	473325-35-8	473325-36-9	473325-37-0	473325-38-1
	473325-40-5	473325-41-6	473325-43-8	473325-44-9	473325-49-4
	473325-50-7	473325-51-8	473325-52-9	473325-53-0	473325-54-1
	473325-55-2	473325-56-3	473325-58-5	473325-62-1	473325-63-2
	473325-65-4	473325-66-5	473325-67-6	473325-68-7	473325-71-2
	473325-75-6	473325-83-6	473325-84-7	473325-86-9	473325-87-0
	473325-88-1	473325-89-2	473325-90-5	473325-91-6	473325-95-0
	473326-01-1	473326-06-6	473326-12-4	473326-14-6	
	473326-15-7	473326-17-9	473326-18-0	473326-19-1	473326-22-6
	473326-23-7	473326-25-9	473326-26-0	473326-27-1	473326-32-8
	473326-35-1	473326-40-8	473326-41-9	473326-46-4	473326-47-5
	473326-48-6	473326-51-1	473326-52-2	473326-53-3	

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L4 ANSWER 6 OF 24 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:857448 HCAPLUS
 DOCUMENT NUMBER: 137:380977
 TITLE: Human nucleic acids and corresponding proteins useful
 in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;
 Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
 Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 25
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XG11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-282739P	P 20010410
			US 2001-283112P	P 20010410
			US 2001-286630P	P 20010425
			WO 2002-US11654	A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressedn in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently...the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

ICI C12
 CC 3-3 (Biochemical Genetics)
 Section cross-reference(s): 1, 6, 9, 14
 IT 473783-98-1 473783-99-2 473784-06-4 473784-07-5 473784-08-6

473784-09-7	473784-11-1	473784-13-3	473784-14-4	473784-15-5
473784-16-6	473784-17-7	473784-18-8	473784-19-9	473784-20-2
473784-21-3	473784-22-4	473784-23-5	473784-24-6	473784-26-8
473784-28-0	473784-29-1	473784-30-4	473784-31-5	473784-32-6
473784-33-7	473784-34-8	473784-35-9	473784-36-0	473784-37-1
473784-38-2	473784-39-3	473784-40-6	473784-41-7	473784-42-8
473784-43-9	473784-44-0	473784-45-1	473784-46-2	473784-48-4
473784-54-2	473784-56-4	473784-59-7	473784-60-0	473784-61-1
473784-62-2	473784-63-3	473784-66-6	473784-68-8	473784-72-4
473784-74-6	473784-76-8	473784-77-9	473784-78-0	473784-80-4
473784-81-5	473784-82-6	473784-83-7	473784-84-8	473784-85-9
473784-87-1	473784-91-7	473784-92-8	473784-94-0	473784-96-2
473784-97-3	473784-98-4	473784-99-5	473785-00-1	473785-01-2
473785-02-3	473785-03-4	473785-04-5	473785-05-6	473785-06-7
473785-07-8	473785-08-9	473785-10-3	473785-12-5	473785-13-6
473785-14-7	473785-15-8	473785-16-9	473785-17-0	473785-18-1
473785-19-2	473785-21-6	473785-23-8	473785-24-9	473785-25-0
473785-26-1	473785-27-2	473785-28-3	473785-29-4	473785-30-7
473785-35-2	473785-36-3	473785-39-6	473785-40-9	473785-41-0
473785-43-2	473785-44-3	473785-45-4	473785-46-5	473785-47-6
473785-49-8	473785-50-1	473785-51-2	473785-53-4	473785-56-7
473785-57-8	473785-58-9	473785-59-0	473785-62-5	473785-63-6
473785-64-7	473785-65-8	473785-68-1	473785-70-5	473785-71-6
473785-73-8	473785-74-9	473785-75-0	473785-76-1	473785-77-2
473785-82-9	473785-83-0	473785-84-1	473785-85-2	473785-87-4
473785-88-5	473785-90-9	473785-91-0	473785-92-1	473785-93-2
473785-94-3	473785-95-4	473785-96-5	473785-98-7	473785-99-8
473786-00-4	473786-01-5	473786-02-6	473786-05-9	473786-07-1
473786-08-2	473786-09-3	473786-12-8	473786-13-9	473786-14-0
473786-15-1	473786-16-2	473786-18-4	473786-23-1	473786-24-2
473786-25-3	473786-28-6	473786-29-7	473786-34-4	473786-35-5
473786-36-6	473786-37-7	473786-38-8	473786-39-9	473786-41-3
473786-42-4	473786-43-5	473786-44-6	473786-45-7	473786-49-1
473786-51-5	473786-52-6	473786-53-7	473786-55-9	473786-56-0
473786-57-1	473786-59-3	473786-65-1	473786-69-5	473786-70-8
473786-71-9	473786-72-0	473786-73-1	473786-74-2	473786-78-6
473786-84-4	473786-86-6	473786-87-7	473786-94-6	473786-95-7
473786-96-8	473786-97-9	473786-99-1	473787-00-7	473787-01-8
473787-03-0	473787-04-1	473787-05-2	473787-06-3	473787-08-5
473787-09-6	473787-10-9	473787-12-1	473787-13-2	473787-14-3
473787-15-4	473787-16-5	473787-18-7	473787-22-3	473787-23-4
473787-25-6	473787-32-5	473787-33-6	473787-34-7	473787-36-9
473787-37-0	473787-38-1	473787-39-2	473787-40-5	473787-44-9
473787-45-0	473787-49-4	473787-51-8	473787-55-2	473787-56-3
473787-58-5	473787-59-6	473787-60-9	473787-62-1	473787-63-2
473787-64-3	473787-65-4	473787-73-4		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT	474751-18-3	474751-19-4	474751-21-8	474751-23-0	474751-24-1
	474751-25-2	474751-31-0	474751-34-3	474751-36-5	474751-37-6
	474751-41-2	474751-48-9	474751-50-3	474751-51-4	474751-52-5
	474751-54-7	474751-55-8	474751-59-2	474751-62-7	474751-67-2
	474751-70-7	474751-72-9	474751-77-4	474751-78-5	474751-79-6
	474751-81-0	474751-94-5	474751-96-7	474751-99-0	474752-01-7
	474752-08-4	474752-13-1	474752-14-2	474752-15-3	474752-16-4
	474752-18-6	474752-25-5	474752-29-9	474752-30-2	474752-31-3
	474752-32-4	474752-33-5	474752-34-6	474752-35-7	474752-36-8

474752-38-0	474752-39-1	474752-44-8	474752-47-1	474752-48-2
474752-52-8	474752-55-1	474752-56-2	474752-59-5	474752-61-9
474752-63-1	474752-65-3	474752-66-4	474752-67-5	474752-69-7
474752-70-0	474752-81-3	474752-87-9	474752-88-0	474752-89-1
474752-90-4	474752-91-5	474752-92-6	474752-93-7	474752-94-8
474752-95-9	474752-96-0	474752-97-1	474752-98-2	474753-04-3
474753-05-4	474753-06-5	474753-07-6	474753-09-8	474753-10-1
474753-11-2	474753-12-3	474753-16-7	474753-18-9	474753-25-8
474753-30-5	474753-32-7	474753-34-9	474753-40-7	474753-46-3
474753-48-5	474753-49-6	474753-51-0	474753-59-8	474753-61-2
474753-71-4	474753-77-0	474753-78-1	474753-79-2	474753-80-5
474753-81-6	474753-82-7	474753-85-0	474753-86-1	474753-87-2
474753-88-3	474753-90-7	474753-91-8	474753-93-0	474753-96-3
474753-98-5	474753-99-6	474754-01-3	474754-03-5	474754-04-6
474754-05-7	474754-07-9	474754-12-6	474754-17-1	474754-24-0
474754-26-2	474754-34-2	474754-35-3	474754-44-4	474754-45-5
474754-64-8	474754-68-2	474754-73-9	474754-87-5	474754-96-6
474755-05-0	474755-07-2	474755-10-7	474755-14-1	474755-17-4
474755-21-0	474755-26-5	474755-27-6	474755-28-7	474755-30-1
474755-33-4	474755-34-5	474755-35-6	474755-38-9	474755-42-5
474755-44-7	474755-45-8	474755-46-9	474755-50-5	474755-52-7
474755-56-1	474755-60-7	474755-75-4	474755-83-4	474755-89-0
474755-90-3	474755-91-4	474755-92-5	474755-98-1	474756-08-6
474756-09-7	474756-10-0	474756-11-1	474756-12-2	474756-13-3
474756-15-5	474756-17-7	474756-19-9	474756-20-2	474756-21-3
474756-22-4	474756-26-8	474756-27-9	474756-28-0	474756-29-1
474756-30-4	474756-31-5	474756-37-1	474756-38-2	474756-42-8
474756-43-9	474756-44-0	474756-49-5	474756-50-8	474756-53-1
474756-59-7	474756-61-1	474756-74-6	474756-79-1	474756-82-6
474756-85-9	474756-87-1	474756-89-3	474756-90-6	474756-91-7
474756-92-8	474756-93-9	474756-94-0	474756-95-1	474756-96-2
474756-97-3	474756-99-5	474757-00-1	474757-01-2	474757-02-3
474757-03-4	474757-05-6	474757-07-8	474757-08-9	474757-12-5
474757-19-2	474757-22-7	474757-24-9	474757-25-0	474757-27-2
474757-32-9	474757-33-0	474757-37-4	474757-40-9	474757-41-0
474757-48-7	474757-49-8	474757-60-3	474757-61-4	474757-62-5
474757-64-7	474757-65-8	474757-66-9	474757-69-2	474757-70-5
474757-72-7	474757-73-8	474757-76-1		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT	474757-78-3	474757-79-4	474757-81-8	474757-82-9	474757-84-1
	474757-86-3	474757-89-6	474757-90-9	474757-92-1	474758-03-7
	474758-04-8	474758-07-1	474758-08-2	474758-09-3	474758-10-6
	474758-14-0	474758-18-4	474758-19-5	474758-23-1	474793-13-0
	474793-14-1	474793-15-2	474793-16-3	474793-17-4	474793-18-5
	474793-19-6	474793-20-9	474793-21-0	474793-22-1	474793-23-2
	474793-24-3	474793-25-4	474793-26-5	474793-27-6	474793-28-7
	474793-29-8	474793-30-1	474793-31-2	474793-32-3	474793-33-4
	474793-34-5	474793-35-6	474793-36-7	474793-37-8	474793-38-9
	474793-39-0	474793-40-3	474793-42-5	474793-43-6	474793-44-7
	474793-45-8	474793-46-9	474793-47-0	474793-48-1	474793-49-2
	474793-50-5	474793-51-6	474793-52-7	474793-53-8	474793-54-9
	474793-55-0	474793-56-1	474793-57-2	474793-58-3	474793-59-4
	474793-60-7	474793-61-8	474793-62-9	474793-63-0	474793-64-1
	474793-65-2	474793-66-3	474793-67-4	474793-68-5	474793-69-6
	474793-70-9	474793-71-0	474793-72-1	474793-73-2	474793-74-3
	474793-75-4	474793-76-5	474793-77-6	474793-78-7	474793-79-8

474793-80-1	474793-81-2	474793-82-3	474793-83-4	474793-84-5
474793-85-6	474793-86-7	474793-88-9	474793-89-0	474793-90-3
474793-91-4	474793-92-5	474793-93-6	474793-94-7	474793-95-8
474793-96-9	474793-97-0	474793-98-1	474794-00-8	474794-01-9
474794-02-0	474794-03-1	474794-04-2	474794-05-3	474794-06-4
474794-07-5	474794-08-6	474794-09-7	474794-10-0	474794-11-1
474794-12-2	474794-13-3	474794-14-4	474794-15-5	474794-16-6
474794-17-7	474794-18-8	474794-19-9	474794-20-2	474794-21-3
474794-22-4	474794-23-5	474794-24-6	474794-25-7	474794-26-8
474794-27-9	474794-28-0	474794-29-1	474794-30-4	474794-32-6
474794-33-7	474794-34-8	474794-35-9	474794-38-2	474794-41-7
474794-43-9	474794-45-1	474794-49-5	474794-57-5	474794-69-9
474794-75-7	474794-77-9	474794-79-1	474794-80-4	474794-81-5
474794-82-6	474794-83-7	474794-84-8	474794-85-9	474794-86-0
474794-87-1	474794-89-3	474794-90-6	474794-91-7	474794-92-8
474794-93-9	474794-94-0	474794-95-1	474794-96-2	474794-97-3
474794-98-4	474794-99-5	474795-00-1	474795-01-2	474795-02-3
474795-03-4	474795-04-5	474795-05-6	474795-06-7	474795-07-8
474795-08-9	474795-09-0	474795-10-3	474795-11-4	474795-12-5
474795-13-6	474795-14-7	474795-15-8	474795-16-9	474795-17-0
474795-18-1	474795-19-2	474795-20-5	474795-21-6	474795-22-7
474795-23-8	474795-24-9	474795-25-0	474795-26-1	474795-27-2
474795-28-3	474795-29-4	474795-30-7	474795-31-8	474795-32-9
474795-34-1	474795-35-2	474795-36-3	474795-37-4	474795-38-5
474795-39-6	474795-41-0	474795-42-1	474795-43-2	474795-44-3
474795-45-4	474795-46-5	474795-47-6	474795-48-7	474795-49-8
474795-50-1	474795-51-2	474795-52-3	474795-53-4	474795-54-5
474795-56-7	474795-60-3	474795-61-4	474795-62-5	474795-63-6
474795-64-7	474795-65-8	474795-66-9	474795-67-0	
474795-68-1	474795-69-2	474795-70-5	474795-71-6	

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L4 ANSWER 7 OF 24 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:857447 HCAPLUS
 DOCUMENT NUMBER: 137:380976
 TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 25
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XF11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,				

UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2002083921 A2 20021024 WO 2002-US11654 20020410
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
 US 2001-283112P P 20010410
 US 2001-286630P P 20010425
 WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.]

ICI C12

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 9, 14

IT	473325-89-2	473325-90-5	473325-91-6	473325-93-8	473325-96-1
	473325-97-2	473326-01-1	473326-14-6	473326-19-1	
	473326-21-5	473326-23-7	473326-25-9	473326-27-1	473326-32-8
	473326-35-1	473326-36-2	473326-38-4	473326-41-9	473326-46-4
	473326-47-5	473326-52-2	473326-53-3	473326-55-5	473326-56-6
	473326-57-7	473326-58-8	473326-68-0	473326-70-4	473326-74-8
	473326-76-0	473326-78-2	473326-81-7	473326-87-3	473326-88-4
	473326-90-8	473326-94-2	473327-04-7	473327-05-8	473327-06-9
	473327-07-0	473327-09-2	473327-13-8	473327-14-9	473327-19-4
	473327-23-0	473327-29-6	473327-30-9	473327-36-5	473327-39-8
	473327-41-2	473327-43-4	473327-45-6	473327-48-9	473327-52-5
	473327-63-8	473327-64-9	473327-65-0	473327-71-8	473327-79-6
	473327-88-7	473328-09-5	473328-10-8	473328-13-1	473328-15-3
	473328-17-5	473328-36-8	473328-37-9	473328-38-0	473328-43-7
	473328-45-9	473328-47-1	473328-54-0	473328-58-4	473328-60-8
	473328-61-9	473328-62-0	473328-63-1	473328-65-3	473328-66-4
	473328-71-1	473328-72-2	473328-73-3	473328-78-8	473328-80-2
	473328-81-3	473328-82-4	473328-84-6	473328-86-8	473328-88-0
	473328-92-6	473328-96-0	473328-97-1	473328-98-2	473328-99-3
	473329-01-0	473329-05-4	473329-13-4	473329-17-8	473329-18-9
	473329-19-0	473329-20-3	473329-21-4	473329-22-5	473329-25-8
	473329-26-9	473329-30-5	473329-31-6	473329-33-8	473329-36-1
	473329-37-2	473329-39-4	473329-40-7	473329-41-8	473329-43-0
	473329-44-1	473329-46-3	473329-47-4	473329-49-6	473329-50-9
	473329-52-1	473329-53-2	473329-54-3	473329-57-6	473329-59-8

473329-60-1	473329-61-2	473329-63-4	473329-79-2	473329-80-5
473329-81-6	473329-83-8	473329-84-9	473329-93-0	473329-94-1
473329-95-2	473330-03-9	473330-07-3	473330-11-9	473330-15-3
473330-20-0	473330-23-3	473330-25-5	473330-35-7	473330-42-6
473330-44-8	473330-45-9	473330-49-3	473330-51-7	473330-55-1
473330-56-2	473330-57-3	473330-58-4	473330-59-5	473330-61-9
473330-67-5	473330-69-7	473330-71-1	473330-72-2	473330-77-7
473330-78-8	473330-79-9	473330-82-4	473330-84-6	473330-85-7
473330-89-1	473330-90-4	473330-91-5	473330-92-6	473330-94-8
473330-96-0	473330-97-1	473331-00-9	473331-01-0	473331-02-1
473331-03-2	473331-04-3	473331-06-5	473331-13-4	473331-14-5
473331-18-9	473331-25-8	473331-26-9	473331-28-1	473331-30-5
473331-45-2	473331-46-3	473331-49-6	473331-53-2	473331-55-4
473331-56-5	473331-57-6	473331-61-2	473331-62-3	473331-63-4
473331-64-5	473331-65-6	473331-66-7	473331-67-8	473331-68-9
473331-72-5	473331-76-9	473331-77-0	473331-78-1	473331-79-2
473331-81-6	473331-82-7	473331-86-1	473331-90-7	473331-91-8
473331-93-0	473331-96-3	473331-97-4	473331-98-5	473331-99-6
473332-00-2	473332-01-3	473332-02-4	473332-03-5	473332-09-1
473332-10-4	473332-11-5	473332-12-6	473332-17-1	473332-18-2
473332-22-8	473332-24-0	473332-25-1	473332-26-2	473332-28-4
473332-29-5	473332-33-1	473332-34-2	473332-35-3	

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

IT	474288-30-7	474288-31-8	474288-32-9	474288-37-4	474288-39-6
	474288-43-2	474288-44-3	474288-46-5	474288-49-8	474288-50-1
	474288-55-6	474288-58-9	474288-59-0	474288-66-9	474288-67-0
	474288-78-3	474288-82-9	474288-84-1	474288-87-4	474288-88-5
	474288-89-6	474288-99-8	474289-14-0	474289-19-5	474289-20-8
	474289-21-9	474289-23-1	474289-24-2	474289-26-4	474289-28-6
	474289-29-7	474289-31-1	474289-32-2	474289-33-3	474289-38-8
	474289-41-3	474289-43-5	474289-49-1	474289-53-7	474289-55-9
	474289-56-0	474289-57-1	474289-61-7	474289-65-1	
	474289-69-5	474289-75-3	474289-81-1	474289-85-5	474289-86-6
	474289-88-8	474290-01-2	474290-05-6	474290-18-1	474290-22-7
	474290-24-9	474290-33-0	474290-37-4	474290-40-9	
	474290-42-1	474290-43-2	474290-44-3	474290-45-4	474290-46-5
	474290-47-6	474290-48-7	474290-49-8	474290-50-1	474290-52-3
	474290-53-4	474290-54-5	474290-57-8	474290-63-6	474290-67-0
	474290-71-6	474290-73-8	474290-75-0	474290-77-2	474290-79-4
	474290-80-7	474290-82-9	474290-88-5	474290-92-1	474290-93-2
	474290-96-5	474291-00-4	474291-03-7	474291-12-8	474291-16-2
	474291-34-4	474291-42-4	474291-43-5	474291-44-6	474291-46-8
	474291-47-9	474291-49-1	474291-50-4	474291-52-6	474291-53-7
	474291-54-8	474291-55-9	474291-56-0	474291-57-1	474291-58-2
	474291-59-3	474291-62-8	474291-64-0	474291-65-1	474291-66-2
	474291-73-1	474291-74-2	474291-76-4	474291-77-5	474291-87-7
	474291-89-9	474291-91-3	474291-97-9	474292-08-5	474292-10-9
	474292-18-7	474292-32-5	474292-34-7	474292-42-7	474292-57-4
	474292-58-5	474292-59-6	474292-61-0	474292-62-1	474292-63-2
	474292-65-4	474292-66-5	474292-67-6	474292-68-7	474292-69-8
	474292-70-1	474292-72-3	474292-75-6	474292-76-7	474292-77-8
	474292-79-0	474292-88-1	474292-90-5	474292-91-6	474292-92-7
	474293-03-3	474293-04-4	474293-05-5	474293-06-6	474293-12-4
	474293-15-7	474293-16-8	474293-18-0	474293-23-7	474293-33-9
	474293-36-2	474293-46-4	474293-47-5	474293-48-6	474293-49-7
	474293-50-0	474293-51-1	474293-52-2	474293-53-3	474293-54-4

474293-55-5	474293-56-6	474293-57-7	474293-58-8	474293-59-9
474293-60-2	474293-61-3	474293-62-4	474293-63-5	474293-64-6
474293-65-7	474293-68-0	474293-69-1	474293-71-5	474293-74-8
474293-76-0	474293-77-1	474293-78-2	474293-80-6	474293-83-9
474293-84-0	474293-85-1	474293-86-2	474293-87-3	474293-88-4
474293-96-4	474293-97-5	474293-98-6	474293-99-7	474294-00-3
474294-03-6	474294-08-1	474294-17-2	474294-19-4	474294-26-3
474294-27-4	474294-28-5	474294-29-6	474294-30-9	474294-31-0
474294-32-1	474294-33-2	474294-34-3	474294-35-4	474294-36-5
474294-37-6	474294-39-8	474294-42-3	474294-43-4	474294-44-5
474294-45-6	474294-49-0	474294-50-3	474294-51-4	474294-52-5
474294-57-0	474294-58-1	474294-62-7	474294-65-0	474294-68-3
474294-74-1	474294-80-9	474294-82-1	474294-84-3	474294-85-4
474294-92-3	474294-94-5	474294-95-6	474294-96-7	474294-97-8

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L4 ANSWER 8 OF 24 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:857446 HCAPLUS

DOCUMENT NUMBER: 137:380975

TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers

INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.

PATENT ASSIGNEE(S): Agensys, Inc., USA

SOURCE: PCT Int. Appl., 1021 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 25

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XE11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-282739P	P 20010410
			US 2001-283112P	P 20010410

US 2001-286630P P 20010425
 WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.]

ICI C12

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 9, 14

IT	474751-96-7	474751-97-8	474751-98-9	474751-99-0	474752-00-6
	474752-01-7	474752-02-8	474752-03-9	474752-04-0	474752-05-1
	474752-06-2	474752-07-3	474752-08-4	474752-09-5	474752-10-8
	474752-11-9	474752-12-0	474752-13-1	474752-14-2	474752-15-3
	474752-16-4	474752-17-5	474752-18-6	474752-19-7	474752-20-0
	474752-21-1	474752-22-2	474752-23-3	474752-24-4	474752-25-5
	474752-26-6	474752-27-7	474752-28-8	474752-29-9	474752-30-2
	474752-31-3	474752-32-4	474752-33-5	474752-34-6	474752-35-7
	474752-36-8	474752-37-9	474752-38-0	474752-39-1	474752-40-4
	474752-41-5	474752-42-6	474752-43-7	474752-44-8	474752-45-9
	474752-46-0	474752-47-1	474752-48-2	474752-50-6	
	474752-51-7	474752-52-8	474752-53-9	474752-54-0	474752-55-1
	474752-56-2	474752-57-3	474752-58-4	474752-59-5	474752-60-8
	474752-61-9	474752-62-0	474752-63-1	474752-64-2	
	474752-65-3	474752-66-4	474752-67-5	474752-68-6	474752-69-7
	474752-70-0	474752-71-1	474752-72-2	474752-73-3	474752-74-4
	474752-75-5	474752-76-6	474752-77-7	474752-78-8	474752-79-9
	474752-80-2	474752-81-3	474752-82-4	474752-84-6	474752-85-7
	474752-86-8	474752-87-9	474752-88-0	474752-89-1	474752-90-4
	474752-91-5	474752-92-6	474752-93-7	474752-94-8	474752-95-9
	474752-96-0	474752-97-1	474752-98-2	474752-99-3	474753-00-9
	474753-01-0	474753-02-1	474753-03-2	474753-04-3	474753-05-4
	474753-06-5	474753-07-6	474753-08-7	474753-09-8	474753-10-1
	474753-11-2	474753-12-3	474753-13-4	474753-14-5	474753-15-6
	474753-16-7	474753-17-8	474753-18-9	474753-19-0	474753-20-3
	474753-21-4	474753-22-5	474753-23-6	474753-24-7	474753-25-8
	474753-26-9	474753-27-0	474753-28-1	474753-29-2	474753-30-5
	474753-31-6	474753-32-7	474753-33-8	474753-34-9	474753-35-0
	474753-36-1	474753-37-2	474753-38-3	474753-39-4	474753-40-7
	474753-41-8	474753-42-9	474753-43-0	474753-44-1	474753-45-2
	474753-46-3	474753-47-4	474753-48-5	474753-49-6	474753-50-9
	474753-51-0	474753-52-1	474753-53-2	474753-54-3	474753-55-4
	474753-56-5	474753-57-6	474753-58-7	474753-59-8	474753-60-1
	474753-61-2	474753-62-3	474753-63-4	474753-64-5	474753-65-6
	474753-66-7	474753-67-8	474753-68-9	474753-69-0	474753-70-3
	474753-71-4	474753-72-5	474753-73-6	474753-74-7	474753-75-8
	474753-76-9	474753-77-0	474753-78-1	474753-79-2	474753-80-5
	474753-81-6	474753-82-7	474753-83-8	474753-84-9	474753-85-0
	474753-86-1	474753-87-2	474753-88-3	474753-89-4	474753-90-7
	474753-91-8	474753-92-9	474753-93-0	474753-94-1	474753-95-2
	474753-96-3	474753-97-4	474753-98-5	474753-99-6	474754-00-2

474754-01-3	474754-02-4	474754-03-5	474754-04-6	474754-05-7
474754-06-8	474754-07-9	474754-08-0	474754-09-1	474754-10-4
474754-11-5	474754-12-6	474754-13-7	474754-14-8	474754-15-9
474754-16-0	474754-17-1	474754-18-2	474754-19-3	474754-20-6
474754-21-7	474754-22-8	474754-23-9	474754-24-0	474754-25-1
474754-26-2	474754-27-3	474754-28-4	474754-29-5	474754-30-8

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L4 ANSWER 9 OF 24 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:857445 HCAPLUS

DOCUMENT NUMBER: 137:334082

TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers

INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.

PATENT ASSIGNEE(S): Agensys, Inc., USA

SOURCE: PCT Int. Appl., 1021 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 25

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XD11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, CO, CR, CU, CZ, DE, DK, DM, GM, HR, HU, ID, IL, IN, IS, LS, LT, LU, LV, MA, MD, MG, PL, PT, RO, RU, SD, SE, UA, UG, UZ, VN, YU, ZA, ZM, RW: GH, GM, KE, LS, MW, MZ, SD, CY, DE, DK, ES, FI, FR, BF, BJ, CF, CG, CI, CM, GA,		BA, BB, BG, BR, BY, BZ, CA, CH, CN, DZ, EC, EE, ES, FI, GB, GD, GE, GH, JP, KE, KG, KP, KR, KZ, LC, LK, LR, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, CO, CR, CU, CZ, DE, DK, DM, GM, HR, HU, ID, IL, IN, IS, LS, LT, LU, LV, MA, MD, MG, PL, PT, RO, RU, SD, SE, UA, UG, UZ, VN, YU, ZA, ZM, RW: GH, GM, KE, LS, MW, MZ, SD, CY, DE, DK, ES, FI, FR, BF, BJ, CF, CG, CI, CM, GA,		BA, BB, BG, BR, BY, BZ, CA, CH, CN, DZ, EC, EE, ES, FI, GB, GD, GE, GH, JP, KE, KG, KP, KR, KZ, LC, LK, LR, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
PRIORITY APPLN. INFO.:			US 2001-282739P	P 20010410
			US 2001-283112P	P 20010410
			US 2001-286630P	P 20010425
			WO 2002-US11654	A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs.

Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.] .

ICI C12
 CC 3-3 (Biochemical Genetics)
 Section cross-reference(s): 1, 6, 9, 14

IT	474288-62-5	474288-66-9	474288-67-0	474288-70-5	474288-71-6
	474288-72-7	474288-73-8	474288-74-9	474288-75-0	474288-77-2
	474288-78-3	474288-79-4	474288-80-7	474288-81-8	474288-82-9
	474288-83-0	474288-84-1	474288-85-2	474288-86-3	474288-87-4
	474288-88-5	474288-89-6	474288-90-9	474288-91-0	474288-92-1
	474288-93-2	474288-94-3	474288-95-4	474288-96-5	474288-97-6
	474288-98-7	474288-99-8	474289-00-4	474289-01-5	474289-02-6
	474289-03-7	474289-04-8	474289-05-9	474289-06-0	474289-07-1
	474289-08-2	474289-09-3	474289-10-6	474289-11-7	474289-12-8
	474289-13-9	474289-14-0	474289-15-1	474289-16-2	474289-17-3
	474289-18-4	474289-19-5	474289-20-8	474289-21-9	474289-22-0
	474289-23-1	474289-24-2	474289-25-3	474289-26-4	474289-27-5
	474289-28-6	474289-29-7	474289-30-0	474289-31-1	474289-32-2
	474289-33-3	474289-38-8	474289-41-3	474289-43-5	474289-47-9
	474289-49-1	474289-51-5	474289-53-7	474289-55-9	474289-56-0
	474289-57-1	474289-58-2	474289-61-7	474289-63-9	474289-65-1
	474289-66-2	474289-67-3	474289-69-5	474289-71-9	474289-73-1
	474289-75-3	474289-77-5	474289-78-6	474289-81-1	474289-83-3
	474289-85-5	474289-86-6	474289-88-8	474289-91-3	474289-92-4
	474289-94-6	474289-96-8	474289-97-9	474289-99-1	474290-01-2
	474290-03-4	474290-05-6	474290-10-3	474290-11-4	474290-12-5
	474290-13-6	474290-14-7	474290-16-9	474290-18-1	474290-20-5
	474290-21-6	474290-22-7	474290-24-9	474290-25-0	474290-27-2
	474290-29-4	474290-31-8	474290-33-0	474290-34-1	
	474290-35-2	474290-36-3	474290-37-4	474290-39-6	474290-40-9
	474290-41-0	474290-42-1	474290-43-2	474290-44-3	474290-45-4
	474290-46-5	474290-47-6	474290-48-7	474290-49-8	474290-50-1
	474290-51-2	474290-52-3	474290-53-4	474290-54-5	474290-55-6
	474290-57-8	474290-59-0	474290-61-4	474290-63-6	474290-65-8
	474290-67-0	474290-69-2	474290-71-6	474290-73-8	474290-75-0
	474290-77-2	474290-78-3	474290-79-4	474290-80-7	474290-81-8
	474290-82-9	474290-83-0	474290-84-1	474290-85-2	474290-86-3
	474290-87-4	474290-88-5	474290-89-6	474290-90-9	474290-91-0
	474290-92-1	474290-93-2	474290-94-3	474290-95-4	474290-96-5
	474290-97-6	474290-98-7	474290-99-8	474291-00-4	474291-01-5
	474291-02-6	474291-03-7	474291-04-8	474291-05-9	474291-06-0
	474291-07-1	474291-08-2	474291-09-3	474291-10-6	474291-11-7
	474291-12-8	474291-13-9	474291-14-0	474291-15-1	474291-16-2
	474291-17-3	474291-18-4	474291-19-5	474291-20-8	474291-21-9
	474291-22-0	474291-23-1	474291-24-2	474291-25-3	474291-26-4
	474291-27-5	474291-28-6	474291-29-7	474291-30-0	474291-31-1
	474291-32-2	474291-33-3	474291-34-4	474291-35-5	474291-36-6
	474291-37-7	474291-38-8	474291-39-9	474291-40-2	474291-41-3
	474291-42-4	474291-43-5	474291-44-6	474291-45-7	474291-46-8
	474291-47-9	474291-48-0	474291-49-1	474291-50-4	474291-51-5
	474291-52-6	474291-53-7	474291-54-8	474291-55-9	474291-56-0
	474291-57-1	474291-58-2	474291-59-3	474291-60-6	

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study);

BIOL (Biological study); USES (Uses)
 (peptide epitopes; human nucleic acids and corresponding proteins
 useful in the detection and treatment of various cancers)

L4 ANSWER 10 OF 24 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:857443 HCAPLUS
 DOCUMENT NUMBER: 137:321378
 TITLE: Human nucleic acids and corresponding proteins useful
 in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;
 Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
 Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 25
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XC11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-282739P	P 20010410
			US 2001-283112P	P 20010410
			US 2001-286630P	P 20010425
			WO 2002-US11654	A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.]

ICI C12
 CC 3-3 (Biochemical Genetics)
 Section cross-reference(s): 1, 6, 9, 14

IT	473785-27-2	473785-28-3	473785-29-4	473785-30-7	473785-31-8
	473785-32-9	473785-33-0	473785-34-1	473785-35-2	473785-36-3
	473785-37-4	473785-38-5	473785-39-6	473785-40-9	473785-41-0
	473785-42-1	473785-43-2	473785-44-3	473785-45-4	473785-46-5
	473785-47-6	473785-48-7	473785-49-8	473785-50-1	473785-51-2
	473785-52-3	473785-53-4	473785-54-5	473785-55-6	473785-56-7
	473785-57-8	473785-58-9	473785-59-0	473785-60-3	473785-61-4
	473785-62-5	473785-63-6	473785-64-7	473785-65-8	473785-66-9
	473785-67-0	473785-68-1	473785-69-2	473785-70-5	473785-71-6
	473785-72-7	473785-73-8	473785-74-9	473785-75-0	473785-76-1
	473785-77-2	473785-78-3	473785-79-4	473785-80-7	473785-81-8
	473785-82-9	473785-83-0	473785-84-1	473785-85-2	473785-86-3
	473785-87-4	473785-88-5	473785-89-6	473785-90-9	473785-91-0
	473785-92-1	473785-93-2	473785-94-3	473785-95-4	473785-96-5
	473785-97-6	473785-98-7	473785-99-8	473786-00-4	473786-01-5
	473786-02-6	473786-03-7	473786-04-8	473786-05-9	473786-06-0
	473786-07-1	473786-08-2	473786-09-3	473786-10-6	473786-11-7
	473786-12-8	473786-13-9	473786-14-0	473786-15-1	473786-16-2
	473786-17-3	473786-18-4	473786-19-5	473786-20-8	473786-21-9
	473786-22-0	473786-23-1	473786-24-2	473786-25-3	473786-26-4
	473786-27-5	473786-28-6	473786-29-7	473786-30-0	473786-31-1
	473786-32-2	473786-33-3	473786-34-4	473786-35-5	473786-36-6
	473786-37-7	473786-38-8	473786-39-9	473786-40-2	473786-41-3
	473786-42-4	473786-43-5	473786-44-6	473786-45-7	473786-46-8
	473786-47-9	473786-48-0	473786-49-1	473786-50-4	473786-51-5
	473786-52-6	473786-53-7	473786-54-8	473786-55-9	473786-56-0
	473786-57-1	473786-58-2	473786-59-3	473786-60-6	473786-61-7
	473786-62-8	473786-63-9	473786-64-0	473786-65-1	473786-66-2
	473786-67-3	473786-68-4	473786-69-5	473786-70-8	473786-71-9
	473786-72-0	473786-73-1	473786-74-2	473786-75-3	473786-76-4
	473786-77-5	473786-78-6	473786-79-7	473786-80-0	473786-81-1
	473786-82-2	473786-83-3	473786-84-4	473786-85-5	473786-86-6
	473786-87-7	473786-88-8	473786-89-9	473786-90-2	473786-91-3
	473786-92-4	473786-93-5	473786-94-6	473786-95-7	473786-96-8
	473786-97-9	473786-98-0	473786-99-1	473787-00-7	473787-01-8
	473787-02-9	473787-03-0	473787-04-1	473787-05-2	473787-06-3
	473787-07-4	473787-08-5	473787-09-6	473787-10-9	473787-11-0
	473787-12-1	473787-13-2	473787-14-3	473787-15-4	473787-16-5
	473787-17-6	473787-18-7	473787-19-8	473787-20-1	473787-21-2
	473787-22-3	473787-23-4	473787-24-5	473787-25-6	473787-26-7
	473787-27-8	473787-28-9	473787-29-0	473787-30-3	473787-31-4
	473787-32-5	473787-33-6	473787-34-7	473787-35-8	473787-36-9
	473787-37-0	473787-38-1	473787-39-2	473787-40-5	473787-41-6
	473787-42-7	473787-43-8	473787-44-9	473787-45-0	473787-46-1
	473787-47-2	473787-48-3	473787-49-4	473787-50-7	473787-51-8
	473787-52-9	473787-53-0	473787-54-1	473787-55-2	473787-56-3
	473787-57-4	473787-58-5	473787-59-6		

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L4 ANSWER 11 OF 24 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:857442 HCPLUS

DOCUMENT NUMBER: 137:321377

TITLE: Human nucleic acids and corresponding proteins useful

INVENTOR(S) : in the detection and treatment of various cancers
 Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary;
 Ge, Wangmao; Hubert, Rene S.; Morrison, Karen;
 Morrison, Robert Kendall; Raitano, Arthur B.

PATENT ASSIGNEE(S) : Agensys, Inc., USA

SOURCE : PCT Int. Appl., 1021 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 25

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XB11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, CO, CR, CU, CZ, DE, DK, DM, GM, HR, HU, ID, IL, IN, IS, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	RW: GH, GM, KE, LS, MW, MZ, SD, BF, BJ, CF, CG, CI, CM, GA,	WO 2002-US11654	20020410	
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, CO, CR, CU, CZ, DE, DK, DM, GM, HR, HU, ID, IL, IN, IS, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	RW: GH, GM, KE, LS, MW, MZ, SD, BF, BJ, CF, CG, CI, CM, GA,	WO 2002-US11654	20020410	
PRIORITY APPLN. INFO.:		US 2001-282739P	P	20010410
		US 2001-283112P	P	20010410
		US 2001-286630P	P	20010425
		WO 2002-US11654	A	20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.]

ICI C12

CC 3-3 (Biochemical Genetics)
 Section cross-reference(s): 1, 6, 9, 14

IT 112747-70-3, 1-15-Galanin (cattle) 473453-66-6 473453-67-7
 473453-68-8 473453-72-4 473453-88-2 473453-91-7 473453-95-1
 473453-97-3 473453-98-4 473453-99-5 473454-02-3
 473454-03-4 473454-04-5 473454-05-6 473454-11-4
 473454-12-5 473454-13-6 473454-23-8 473454-27-2 473454-29-4

473454-30-7	473454-35-2	473454-38-5	473454-43-2	473597-23-8
473597-24-9	473597-25-0	473597-26-1	473597-27-2	473597-28-3
473597-29-4	473597-30-7	473597-31-8	473597-32-9	473597-33-0
473597-34-1	473597-35-2	473597-36-3	473597-37-4	473597-38-5
473597-39-6	473597-40-9	473597-41-0	473597-42-1	473597-43-2
473597-44-3	473597-45-4	473597-46-5	473597-47-6	473597-48-7
473597-49-8	473597-50-1	473597-51-2	473597-52-3	473597-53-4
473597-54-5	473597-55-6	473597-56-7	473597-57-8	473597-58-9
473597-59-0	473597-60-3	473597-61-4	473597-62-5	473597-63-6
473597-64-7	473597-65-8	473597-66-9	473597-67-0	473597-68-1
473597-69-2	473597-70-5	473597-71-6	473597-72-7	473597-73-8
473597-74-9	473597-75-0	473597-76-1	473597-77-2	473597-78-3
473597-79-4	473597-80-7	473597-81-8	473597-82-9	473597-83-0
473597-84-1	473597-85-2	473597-86-3	473597-87-4	473597-88-5
473597-89-6	473597-90-9	473597-91-0	473597-92-1	473597-93-2
473597-94-3	473597-95-4	473597-96-5	473597-97-6	473597-98-7
473597-99-8	473598-00-4	473598-01-5	473598-02-6	473598-03-7
473598-04-8	473598-05-9	473598-06-0	473598-07-1	473598-08-2
473598-09-3	473598-10-6	473598-11-7	473598-12-8	473598-13-9
473598-14-0	473598-16-2	473598-17-3	473598-19-5	473598-21-9
473598-23-1	473598-24-2	473598-25-3	473598-26-4	473598-27-5
473598-28-6	473598-32-2	473598-34-4	473598-35-5	473598-36-6
473598-37-7	473598-38-8	473598-39-9	473598-40-2	473598-41-3
473598-42-4	473598-43-5	473598-44-6	473598-45-7	473598-46-8
473598-47-9	473598-48-0	473598-49-1	473598-50-4	473598-51-5
473598-52-6	473598-53-7	473598-54-8	473598-55-9	473598-56-0
473598-57-1	473598-58-2	473598-59-3	473598-60-6	473598-61-7
473598-62-8	473598-63-9	473598-64-0	473598-65-1	473598-66-2
473598-67-3	473598-68-4	473598-69-5	473598-70-8	473598-71-9
473598-72-0	473598-73-1	473598-74-2	473598-75-3	473598-76-4
473598-77-5	473598-78-6	473598-79-7	473598-80-0	473598-81-1
473598-82-2	473598-83-3	473598-84-4	473598-85-5	473598-86-6
473598-87-7	473598-88-8	473598-89-9	473598-90-2	473598-91-3
473598-92-4	473598-93-5	473598-94-6	473598-95-7	473598-96-8
473598-97-9	473598-98-0	473598-99-1	473599-00-7	473599-01-8
473599-02-9	473599-03-0	473599-04-1	473599-05-2	473599-06-3
473599-07-4	473599-08-5	473599-09-6	473599-10-9	473599-11-0
473599-12-1	473599-13-2	473599-14-3	473599-15-4	473599-16-5
473599-17-6	473599-18-7	473599-19-8	473599-20-1	473599-21-2
473599-22-3	473599-23-4	473599-24-5	473599-25-6	473599-26-7
473599-27-8	473599-28-9	473599-29-0	473599-30-3	473599-31-4
473599-32-5	473599-33-6	473599-34-7	473599-35-8	473599-36-9
473599-37-0	473599-38-1			

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L4 ANSWER 12 OF 24 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:857436 HCAPLUS

DOCUMENT NUMBER: 137:321376

TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers

INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.

PATENT ASSIGNEE(S): Agensys, Inc., USA

SOURCE: PCT Int. Appl., 1021 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 25
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083921	A2	20021024	WO 2002-XA11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2002083921	A2	20021024	WO 2002-US11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2001-282739P	P 20010410
			US 2001-283112P	P 20010410
			US 2001-286630P	P 20010425
			WO 2002-US11654	A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

ICI C12
 CC 3-3 (Biochemical Genetics)
 Section cross-reference(s): 1, 6, 9, 14
 IT 103928-90-1 473452-73-2 473452-74-3 473452-75-4 473452-76-5
 473452-77-6 473452-78-7 473452-79-8 473452-80-1 473452-82-3
 473452-86-7 473452-90-3 473452-92-5 473452-94-7 473452-95-8
 473452-96-9 473452-97-0 473452-99-2 473453-01-9 473453-02-0
 473453-03-1 473453-04-2 473453-05-3 473453-06-4 473453-07-5
 473453-08-6 473453-09-7 473453-10-0 473453-11-1
 473453-12-2 473453-13-3 473453-14-4 473453-15-5 473453-16-6
 473453-17-7 473453-18-8 473453-19-9 473453-20-2 473453-21-3
 473453-22-4 473453-23-5 473453-24-6 473453-25-7 473453-26-8
 473453-27-9 473453-28-0 473453-29-1 473453-30-4 473453-31-5
 473453-32-6 473453-33-7 473453-34-8 473453-35-9 473453-36-0
 473453-37-1 473453-38-2 473453-39-3 473453-40-6 473453-41-7

473453-42-8 ···· 473453-43-9 ··· 473453-44-0 ··· 473453-45-1 ··· 473453-46-2 ···
 473453-47-3 473453-48-4 473453-49-5 473453-50-8
 473453-51-9 473453-52-0 473453-53-1 473453-54-2 473453-55-3
 473453-56-4 473453-57-5 473453-58-6 473453-59-7 473453-60-0
 473453-61-1 473453-62-2 473453-63-3 473453-64-4 473453-65-5
 473453-66-6 473453-67-7 473453-68-8 473453-69-9 473453-70-2
 473453-71-3 473453-72-4 473453-73-5 473453-74-6 473453-75-7
 473453-76-8 473453-77-9 473453-78-0 473453-79-1 473453-80-4
 473453-81-5 473453-82-6 473453-83-7 473453-84-8 473453-85-9
 473453-86-0 473453-87-1 473453-88-2 473453-89-3 473453-90-6
 473453-91-7 473453-92-8 473453-93-9 473453-94-0 473453-95-1
 473453-96-2 473453-97-3 473453-98-4 473453-99-5
 473454-00-1 473454-01-2 473454-02-3 473454-03-4 473454-04-5
 473454-05-6 473454-06-7 473454-07-8 473454-11-4 473454-12-5
 473454-13-6 473454-14-7 473454-15-8 473454-16-9 473454-17-0
 473454-18-1 473454-19-2 473454-20-5 473454-21-6 473454-22-7
 473454-23-8 473454-24-9 473454-25-0 473454-26-1 473454-27-2
 473454-28-3 473454-29-4 473454-30-7 473454-31-8 473454-32-9
 473454-33-0 473454-34-1 473454-35-2 473454-36-3 473454-37-4
 473454-38-5 473454-39-6 473454-40-9 473454-41-0 473454-42-1
 473454-43-2 473454-44-3 473454-45-4 473454-46-5 473454-47-6
 473454-48-7 473454-49-8 473454-50-1 473454-51-2 473454-52-3
 473454-53-4 473454-54-5 473454-55-6 473454-56-7 473454-57-8
 473454-58-9 473454-59-0 473454-60-3 473454-61-4 473454-62-5
 473454-63-6 473454-65-8 473454-67-0 473454-69-2 473454-70-5
 473454-72-7 473454-74-9 473454-75-0 473454-76-1 473454-77-2
 473454-78-3 473454-79-4 473454-80-7 473454-81-8 473454-82-9
 473454-83-0 473454-84-1 473454-85-2 473454-86-3 473454-87-4
 473454-88-5 473454-89-6 473454-90-9 473454-91-0 473454-92-1
 473454-93-2 473454-94-3 473454-95-4 473454-96-5 473454-97-6
 473454-98-7 473455-00-4 473455-01-5 473455-02-6 473455-03-7
 473455-04-8 473455-05-9 473455-06-0 473455-07-1 473455-08-2
 473455-09-3 473455-10-6 473455-11-7 473455-12-8 473455-13-9
 473455-14-0 473455-15-1 473455-16-2 473455-17-3 473455-18-4
 473455-19-5 473455-20-8 473455-21-9 473455-22-0 473455-23-1
 473455-24-2

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L4 ANSWER 13 OF 24 HCPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:814341 HCPLUS
 DOCUMENT NUMBER: 137:334071
 TITLE: Human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
 INVENTOR(S): Jakobovits, Aya; Challita-Eid, Pia M.; Faris, Mary; Ge, Wangmao; Hubert, Rene S.; Morrison, Karen; Morrison, Robert Kendall; Raitano, Arthur B.
 PATENT ASSIGNEE(S): Agensys, Inc., USA
 SOURCE: PCT Int. Appl., 1021 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 25
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

WO 2002083921	A2	20021024	WO 2002-US11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, CO, CR, CU, CZ, DE, DK, DM, GM, HR, HU, ID, IL, IN, IS, LS, LT, LU, LV, MA, MD, MG, PL, PT, RO, RU, SD, SE, SG, UA, UG, UZ, VN, YU, ZA, ZM,	BA, BB, BG, BR, BY, BZ, CA, CH, CN, DZ, EC, EE, ES, FI, GB, GD, GE, GH, JP, KE, KG, KP, KR, KZ, LC, LK, LR, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, CY, DE, DK, ES, FI, FR, GB, BF, BJ, CF, CG, CI, CM, GA,	SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, GR, IE, IT, LU, MC, NL, PT, SE, TR, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-XA11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, CO, CR, CU, CZ, DE, DK, DM, GM, HR, HU, ID, IL, IN, IS, LS, LT, LU, LV, MA, MD, MG, PL, PT, RO, RU, SD, SE, SG, UA, UG, UZ, VN, YU, ZA, ZM,	BA, BB, BG, BR, BY, BZ, CA, CH, CN, DZ, EC, EE, ES, FI, GB, GD, GE, GH, JP, KE, KG, KP, KR, KZ, LC, LK, LR, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, CY, DE, DK, ES, FI, FR, GB, BF, BJ, CF, CG, CI, CM, GA,	SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, GR, IE, IT, LU, MC, NL, PT, SE, TR, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-XB11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, CO, CR, CU, CZ, DE, DK, DM, GM, HR, HU, ID, IL, IN, IS, LS, LT, LU, LV, MA, MD, MG, PL, PT, RO, RU, SD, SE, SG, UA, UG, UZ, VN, YU, ZA, ZM,	BA, BB, BG, BR, BY, BZ, CA, CH, CN, DZ, EC, EE, ES, FI, GB, GD, GE, GH, JP, KE, KG, KP, KR, KZ, LC, LK, LR, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, CY, DE, DK, ES, FI, FR, GB, BF, BJ, CF, CG, CI, CM, GA,	SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, GR, IE, IT, LU, MC, NL, PT, SE, TR, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-XC11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, CO, CR, CU, CZ, DE, DK, DM, GM, HR, HU, ID, IL, IN, IS, LS, LT, LU, LV, MA, MD, MG, PL, PT, RO, RU, SD, SE, SG, UA, UG, UZ, VN, YU, ZA, ZM,	BA, BB, BG, BR, BY, BZ, CA, CH, CN, DZ, EC, EE, ES, FI, GB, GD, GE, GH, JP, KE, KG, KP, KR, KZ, LC, LK, LR, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, CY, DE, DK, ES, FI, FR, GB, BF, BJ, CF, CG, CI, CM, GA,	SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, GR, IE, IT, LU, MC, NL, PT, SE, TR, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-XD11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, CO, CR, CU, CZ, DE, DK, DM, GM, HR, HU, ID, IL, IN, IS, LS, LT, LU, LV, MA, MD, MG, PL, PT, RO, RU, SD, SE, SG, UA, UG, UZ, VN, YU, ZA, ZM,	BA, BB, BG, BR, BY, BZ, CA, CH, CN, DZ, EC, EE, ES, FI, GB, GD, GE, GH, JP, KE, KG, KP, KR, KZ, LC, LK, LR, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, CY, DE, DK, ES, FI, FR, GB, BF, BJ, CF, CG, CI, CM, GA,	SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, GR, IE, IT, LU, MC, NL, PT, SE, TR, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-XE11654	20020410
W: AE, AG, AL, AM, AT, AU, AZ, CO, CR, CU, CZ, DE, DK, DM, GM, HR, HU, ID, IL, IN, IS, LS, LT, LU, LV, MA, MD, MG, PL, PT, RO, RU, SD, SE, SG, UA, UG, UZ, VN, YU, ZA, ZM,	BA, BB, BG, BR, BY, BZ, CA, CH, CN, DZ, EC, EE, ES, FI, GB, GD, GE, GH, JP, KE, KG, KP, KR, KZ, LC, LK, LR, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW: GH, GM, KE, LS, MW, MZ, SD, CY, DE, DK, ES, FI, FR, GB, BF, BJ, CF, CG, CI, CM, GA,	SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, GR, IE, IT, LU, MC, NL, PT, SE, TR, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

WO 2002083921	A2	20021024	WO 2002-XL11654	20020410
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-XM11654	20020410
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-XN11654	20020410
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2002083921	A2	20021024	WO 2002-XO11654	20020410
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2001-282739P P 20010410
 US 2001-283112P P 20010410
 US 2001-286630P P 20010425
 WO 2002-US11654 A 20020410

AB Eighteen genes and their resp. encoded proteins, and variants thereof, are described wherein the gene exhibits restricted expression in normal adult tissue and is overexpressed in various cancers. Suppression subtractive hybridization (SSH) is used to identify cDNAs corresponding to genes that are differentially expressed in cancer; PCR amplification, cloning, and sequencing of gene fragments from SSH yield the full-length cDNAs. Consequently, the gene products provide diagnostic, prognostic, prophylactic, and/or therapeutic targets for cancer. The genes or fragment thereof, their encoded proteins, or variants or fragments thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with the gene products can be used in active or passive immunization. [This abstr. record is one of 16 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.]

IC ICM C12Q
 CC 3-3 (Biochemical Genetics)

Section cross-reference(s) : 1, 6, 9, 14

IT 473325-83-6 473325-84-7 473325-85-8 473325-86-9 473325-87-0
 473325-88-1 473325-89-2 473325-90-5 473325-91-6 473325-92-7
 473325-93-8 473325-94-9 473325-95-0 473325-96-1 473325-97-2
 473325-98-3 473325-99-4 473326-00-0 473326-01-1
 473326-02-2 473326-03-3 473326-04-4 473326-05-5 473326-06-6
 473326-07-7 473326-08-8 473326-09-9 473326-10-2 473326-11-3
 473326-12-4 473326-13-5 473326-14-6 473326-15-7 473326-16-8
 473326-17-9 473326-18-0 473326-19-1 473326-20-4 473326-21-5
 473326-22-6 473326-23-7 473326-24-8 473326-25-9 473326-26-0
 473326-27-1 473326-28-2 473326-29-3 473326-30-6 473326-31-7
 473326-32-8 473326-33-9 473326-34-0 473326-35-1 473326-36-2
 473326-37-3 473326-38-4 473326-39-5 473326-40-8 473326-41-9
 473326-42-0 473326-43-1 473326-44-2 473326-45-3 473326-46-4
 473326-47-5 473326-48-6 473326-49-7 473326-50-0 473326-51-1
 473326-52-2 473326-53-3 473326-54-4 473326-55-5 473326-56-6
 473326-57-7 473326-58-8 473326-59-9 473326-60-2 473326-61-3
 473326-62-4 473326-63-5 473326-64-6 473326-65-7 473326-66-8
 473326-67-9 473326-68-0 473326-69-1 473326-70-4 473326-71-5
 473326-72-6 473326-73-7 473326-74-8 473326-75-9 473326-76-0
 473326-77-1 473326-78-2 473326-79-3 473326-80-6 473326-81-7
 473326-82-8 473326-83-9 473326-84-0 473326-85-1 473326-86-2
 473326-87-3 473326-88-4 473326-89-5 473326-90-8 473326-91-9
 473326-92-0 473326-93-1 473326-94-2 473326-95-3 473326-96-4
 473326-97-5 473326-98-6 473326-99-7 473327-00-3 473327-01-4
 473327-02-5 473327-03-6 473327-04-7 473327-05-8 473327-06-9
 473327-07-0 473327-08-1 473327-09-2 473327-10-5 473327-11-6
 473327-12-7 473327-13-8 473327-14-9 473327-15-0 473327-16-1
 473327-17-2 473327-18-3 473327-19-4 473327-20-7 473327-21-8
 473327-22-9 473327-23-0 473327-24-1 473327-25-2 473327-26-3
 473327-27-4 473327-28-5 473327-29-6 473327-30-9 473327-31-0
 473327-32-1 473327-33-2 473327-34-3 473327-35-4 473327-36-5
 473327-37-6 473327-38-7 473327-39-8 473327-40-1 473327-41-2
 473327-42-3 473327-43-4 473327-44-5 473327-45-6 473327-46-7
 473327-47-8 473327-48-9 473327-49-0 473327-50-3 473327-51-4
 473327-52-5 473327-53-6 473327-54-7 473327-55-8 473327-56-9
 473327-57-0 473327-58-1 473327-59-2 473327-60-5 473327-61-6
 473327-62-7 473327-63-8 473327-64-9 473327-65-0 473327-66-1
 473327-67-2 473327-68-3 473327-69-4 473327-70-7 473327-71-8
 473327-72-9 473327-73-0 473327-74-1 473327-75-2 473327-76-3
 473327-77-4 473327-78-5 473327-79-6 473327-80-9 473327-81-0
 473327-82-1 473327-83-2 473327-84-3 473327-85-4 473327-86-5
 473327-87-6 473327-88-7 473327-89-8 473327-90-1 473327-91-2
 473327-92-3 473327-93-4 473327-94-5 473327-95-6 473327-96-7
 473327-97-8 473327-98-9 473327-99-0 473328-00-6 473328-01-7
 473328-02-8 473328-03-9 473328-04-0 473328-05-1 473328-06-2
 473328-07-3 473328-08-4 473328-09-5 473328-10-8 473328-11-9
 473328-12-0 473328-13-1 473328-14-2 473328-15-3

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(peptide epitope; human nucleic acids and corresponding proteins useful in the detection and treatment of various cancers)

L4 ANSWER 14 OF 24 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:405386 HCPLUS

DOCUMENT NUMBER: 137:137425

TITLE: Molecular characterization of metallo-beta-lactamase-producing *Acinetobacter baumannii* and *Acinetobacter* genomospecies 3 from Korea: identification of two new

AUTHOR(S) : integrons carrying the blaVIM-2 gene cassettes
 Yum, Jong Hwa; Yi, Keonsoo; Lee, Hyukmin; Yong,
 Dongeun; Lee, Kyungwon; Kim, June Myung; Rossolini,
 Gian Maria; Chong, Yunsop

CORPORATE SOURCE : Department of Clinical Pathology, Research Institute
 of Bacterial Resistance, Yonsei University College of
 Medicine, Seoul, 120-752, S. Korea

SOURCE : Journal of Antimicrobial Chemotherapy (2002), 49(5),
 837-840

PUBLISHER : CODEN: JACHDX; ISSN: 0305-7453
 Oxford University Press

DOCUMENT TYPE : Journal

LANGUAGE : English

AB Carbapenem-resistant *Acinetobacter* spp. used to be rare, but are
 increasingly isolated in Korea. Among 28 isolates of imipenem-resistant
Acinetobacter spp. found in a Korean hospital in 1998 and 1999, 14
 produced metallo-.beta.-lactamases. The blaVIM-2 gene was detected, by
 PCR, in 11 and two isolates of *Acinetobacter baumannii* and *Acinetobacter*
 genomospecies 3, resp., and blaIMP-1 in one isolate of *A. baumannii*. The
 MICs of imipenem for the isolates were 8-32 mg/L. PFGE anal. of
 SmaI-digested genomic DNA gave identical patterns in eight of 11
 blaVIM-2-pos. *A. baumannii* isolates from respiratory specimens of ICU
 patients. The blaVIM-2 gene cassettes in the isolates are identical to
 those from *Pseudomonas aeruginosa* isolates in Europe, but are inserted
 into new class I integrons In105 and In106. The attC site of the last
 cassette of the array in In106 is interrupted by the insertion of a
 putative class II intron. This is the first report of VIM-2
 .beta.-lactamase-producing *A. baumannii* and *Acinetobacter* genomospecies 3.
 Prod'n. of the VIM-2 enzyme presents an emerging threat of carbapenem
 resistance among *Acinetobacter* spp. in Korea.

CC 10-5 (Microbial, Algal, and Fungal Biochemistry)
 Section cross-reference(s) : 3

IT 256335-51-0 444319-65-7 444392-43-2 444392-44-3
 444392-45-4 444392-46-5 444392-47-6 444392-48-7 444392-49-8
 444392-50-1 444392-51-2 444642-23-3

RL: BSU (Biological study, unclassified); PRP (Properties); BIOL
 (Biological study)
 (amino acid sequence; two new integrons carrying the blaVIM-2 gene
 cassettes encoding .beta.-lactamase from *Acinetobacter baumannii* and
Acinetobacter genomospecies 3 isolated in Korea)

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 24 HCPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:314975 HCPLUS

DOCUMENT NUMBER: 136-320410

TITLE: Novel secreted proteins LP102, LP187, LP190 and LP241,
 their cDNAs and therapeutic and diagnostic use thereof

INVENTOR(S) : Lu, Deshun; Song, Ho Yeong; Su, Eric Wen; Wang, He

PATENT ASSIGNEE(S) : Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 148 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2002032939	A2	20020425	WO 2001-US27759	20011010

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES,
 FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
 MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL,
 TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY,
 KG, KZ, MD, RU

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2000-241813P P 20001019

AB The invention provides protein and cDNA sequences for four novel human secreted proteins, named as LP102, LP187, LP190 and LP241, which are called LP protein in general. LP102 is a new member of the ADAM family (contg. "A Disintegrin And Metalloprotease" domain, also known as adamalysin) based on sequence similarity. LP102 also shares sequence homol. with human and mouse PH30 .beta. chain sperm protein and tMDC III. LP187 has sequence homol. with mouse liver cancer-originated growth factor (LCGF), lung growth factor variant (LGF), lens epithelium-derived growth factor (LEDGF), and hepatoma-derived growth factor (HDGF). LP190 is a sequence homolog of carboxypeptidase A and its mRNA tissue expression profile is also provided. LP190 gene is localized to chromosome 7q31. LP241 has sequence similarity with IGF binding protease. The invention also relates to vectors for recombinant expression of the cloned genes, host cells, and antibodies directed to said LP protein. The invention provides the use of polypeptide and polynucleotide in a method for treatment of various kinds of disease.

IC ICM C07K014-00

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 1, 6, 13, 63

IT	413565-89-6	413565-90-9	413565-91-0	413565-92-1
	413565-93-2	413565-94-3	413565-95-4	413565-96-5
	413565-98-7	413565-99-8	413566-00-4	413566-01-5
	413566-03-7	413566-04-8	413566-05-9	413566-06-0
	413566-08-2	413566-09-3	413566-10-6	413566-11-7
	413566-13-9	413566-14-0	413566-15-1	413566-16-2
	413566-18-4	413566-19-5	413566-20-8	413566-21-9
	413566-23-1	413566-24-2	413566-25-3	413566-26-4
	413566-28-6	413566-29-7	413566-30-0	413566-31-1
	413566-33-3	413566-34-4	413566-35-5	413566-36-6
	413566-38-8	413566-39-9	413566-40-2	413566-41-3
	413566-43-5	413566-44-6	413566-45-7	413566-46-8
	413566-48-0	413566-49-1	413566-50-4	413566-51-5
	413566-53-7	413566-54-8	413566-55-9	413566-56-0
	413566-58-2	413566-59-3	413566-60-6	413566-61-7
	413566-63-9	413566-64-0	413566-65-1	413566-66-2
	413566-68-4	413566-69-5	413566-70-8	413566-71-9
	413566-73-1	413566-74-2	413566-75-3	413566-76-4
	413566-78-6	413566-79-7	413566-80-0	413566-81-1
	413566-83-3	413566-84-4	413566-85-5	413566-86-6
	413566-88-8	413566-89-9	413566-90-2	413566-91-3
	413566-93-5	413566-94-6	413566-95-7	413566-96-8
	413566-98-0	413566-99-1	413567-00-7	413567-01-8
	413567-03-0	413567-04-1	413567-05-2	413567-06-3
	413567-08-5	413567-09-6	413567-10-9	413567-11-0
	413567-13-2	413567-14-3	413567-15-4	413567-16-5
	413567-18-7	413567-19-8	413567-20-1	413567-21-2
	413567-23-4	413567-24-5	413567-25-6	413567-28-9
	413567-33-6	413567-34-7	413567-35-8	413567-36-9
	413567-38-1	413567-40-5	413567-41-6	413567-42-7

413567-44-9 413567-45-0 413567-46-1 413567-47-2 413567-48-3
 413567-49-4 413567-50-7 413567-51-8 413567-52-9 413567-53-0
 413567-54-1 413567-55-2 413567-56-3 413637-30-6 413637-31-7
 413637-34-0 413637-35-1

RL: PRP (Properties)

(unclaimed sequence; novel secreted proteins LP102, LP187, LP190 and LP241; their cDNAs and therapeutic and diagnostic use thereof)

L4 ANSWER 16 OF 24 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:763326 HCAPLUS
 DOCUMENT NUMBER: 135:298809
 TITLE: Prion-binding ligands and methods of using same
 INVENTOR(S): Hammond, David J.; Wiltshire, Vite Rose; Carbonell, Ruben; Shen, Honglue
 PATENT ASSIGNEE(S): V.I Technologies, Inc., USA
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077687	A2	20011018	WO 2001-US11150	20010405
WO 2001077687	A3	20020523		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2000-543188 A2 20000405

OTHER SOURCE(S): MARPAT 135:298809

AB Disclosed are ligands that bind to regions of the prion peptide and methods of using same for detecting and isolating prion protein and for diagnosis and treatment of prion diseases. Also disclosed are methods for screening libraries for ligands to prions and for removal of prion protein from a biol. or environmental sample.

IC ICM G01N033-68

CC 1-11 (Pharmacology)

Section cross-reference(s): 9, 15, 17, 19

IT 366455-93-8 366455-94-9 366455-95-0 366455-96-1
 366455-97-2 366455-98-3 366455-99-4 366456-00-0 366456-01-1
 366456-02-2 366456-03-3 366456-04-4 366456-05-5
 366456-07-7 366456-08-8 366456-09-9 366456-11-3 366456-13-5
 366456-14-6 366456-15-7 366456-17-9 366456-19-1
 366456-20-4 366456-22-6 366456-24-8 366456-26-0
 366456-28-2 366456-30-6 366456-32-8

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(as prion ligand; prion-binding ligands and methods of using same for detecting and isolating prion proteins and for diagnosis and treatment of prion diseases)

L4 ANSWER 17 OF 24 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:624615 HCAPLUS
 DOCUMENT NUMBER: 135:328135
 TITLE: Nucleic acids containing single nucleotide polymorphisms in the human genome
 INVENTOR(S): Shimkets, Richard A.; Leach, Martin
 PATENT ASSIGNEE(S): Curagen Corp., USA
 SOURCE: PCT Int. Appl., 4144 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047944	A2	20010705	WO 2000-US35498	20001228
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1244688	A1	20021002	EP 2000-993615	20001228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 1999-173419P	P 19991228
			WO 2000-US35498	W 20001228

AB The invention provides 7867 nucleic acids contg. single-nucleotide polymorphisms (SNPs) identified for transcribed human sequences, as well as methods of using the nucleic acids. The polymorphisms are arranged in the order: 5696 nucleotide sequences for SNPs that are silent; 315 nucleotide sequences for SNPs that lead to conservative amino acid changes; 729 nucleotide changes for SNPs that lead to nonconservative amino acid changes; and 1127 nucleotide sequences for SNPs that involve a gap. The polymorphisms may be detected using allele-specific oligonucleotides that hybridize to the polymorphic site, and have applications in forensic analyses and disease diagnosis. [This abstr. record is the second of 2 records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.].

IC C07H021-04; C07H021-02; C12Q001-68; C07K014-47; C07K016-18; G01N033-53; A61K048-00; A61K039-395; A61K038-00

CC 3-3 (Biochemical Genetics)
 Section cross-reference(s): 13

IT 869-19-2 5156-22-9 350613-78-4 350618-43-8 364318-56-9
 364318-57-0 364318-58-1 364318-59-2 364318-60-5 364318-61-6
 364318-62-7 364318-63-8 364318-64-9 364318-65-0 364318-66-1
 364318-67-2 364318-68-3 364318-69-4 364318-70-7 364318-71-8
 364318-72-9 364318-73-0 364318-74-1 364318-75-2 364318-76-3
 364318-77-4 364318-78-5 364318-79-6 364318-80-9 364318-81-0
 364318-82-1 364318-83-2 364318-84-3 364318-85-4 364318-86-5
 364318-87-6 364318-88-7 364318-89-8 364318-90-1 364318-91-2
 364318-92-3 364318-93-4 364318-94-5 364318-95-6 364318-96-7
 364318-97-8 364318-98-9 364318-99-0 364319-00-6 364319-01-7
 364319-02-8 364319-03-9 364319-04-0 364319-05-1 364319-06-2
 364319-07-3 364319-08-4 364319-09-5 364319-10-8 364319-11-9
 364319-12-0 364319-13-1 364319-14-2 364319-15-3 364319-16-4

Lucas 09/543,188

364319-17-5	364319-18-6	364319-19-7	364319-20-0	364319-21-1
364319-22-2	364319-23-3	364319-24-4	364319-25-5	364319-26-6
364319-27-7	364319-28-8	364319-29-9	364319-30-2	
364319-31-3	364319-32-4	364319-33-5	364319-34-6	364319-35-7
364319-36-8	364319-37-9	364319-38-0	364319-39-1	364319-40-4
364319-41-5	364319-42-6	364319-43-7	364319-44-8	364319-45-9
364319-46-0	364319-47-1	364319-48-2	364319-49-3	364319-50-6
364319-51-7	364319-52-8	364319-53-9	364319-54-0	364319-55-1
364319-56-2	364319-57-3	364319-58-4	364319-59-5	364319-60-8
364319-61-9	364319-62-0	364319-63-1	364319-64-2	364319-65-3
364319-66-4	364319-67-5	364319-68-6	364319-69-7	364319-70-0
364319-71-1	364319-72-2	364319-73-3	364319-74-4	364319-75-5
364319-76-6	364319-77-7	364319-78-8	364319-79-9	364319-80-2
364319-81-3	364319-82-4	364319-83-5	364319-84-6	364319-85-7
364319-86-8	364319-87-9	364320-27-4	364320-28-5	364320-29-6
364320-30-9	364320-31-0	364320-32-1	364320-33-2	364320-34-3
364320-35-4	364320-37-6	364320-38-7	364320-39-8	364320-40-1
364320-41-2	364320-42-3	364320-43-4	364320-44-5	364320-45-6
364320-46-7	364320-51-4	364320-52-5	364320-53-6	364320-54-7
364320-58-1	364320-59-2	364320-60-5	364320-61-6	364320-62-7
364320-63-8	364320-64-9	364320-65-0	364320-66-1	364320-67-2
364320-68-3	364320-69-4	364320-70-7	364320-71-8	364320-72-9
364320-73-0	364320-81-0	364320-82-1	364320-83-2	364320-85-4
364320-86-5	364320-87-6	364320-88-7	364320-90-1	364320-91-2
364320-92-3	364320-93-4	364320-94-5	364320-95-6	364320-96-7
364320-97-8	364320-98-9	364320-99-0	364321-00-6	364321-01-7
364321-03-9	364321-12-0	364321-13-1	364321-14-2	364321-15-3
364321-16-4	364321-17-5	364321-18-6	364321-19-7	364321-20-0
364321-21-1	364321-22-2	364321-23-3	364321-24-4	364321-25-5
364321-26-6	364321-27-7	364321-28-8	364321-29-9	364321-30-2
364321-34-6	364321-36-8	364321-38-0	364321-39-1	364321-40-4
364321-60-8	364322-05-4	364322-40-7	364322-75-8	364323-03-5
364323-44-4	364323-70-6	364323-94-4	364324-21-0	364324-35-6
364324-39-0	364324-40-3	364324-42-5		

RL: ANT (Analyte); BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); ANST (Analytical study); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(polymorphic site sequence; nucleic acids contg. single nucleotide polymorphisms in the human genome)

L4 ANSWER 18 OF 24 HCPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:489670 HCPLUS
DOCUMENT NUMBER: 135:88016
TITLE: Nucleic acids containing single nucleotide polymorphisms in the human genome
INVENTOR(S): Shimkets, Richard A.; Leach, Martin
PATENT ASSIGNEE(S): Curagen Corp.; USA
SOURCE: PCT Int. Appl., 484 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001048245	A2	20010705	WO 2000-US35346	20001227
WO 2001048245	A3	20021128		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CE, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 1999-472688 A2 19991227

AB The invention provides 651 nucleic acids contg. single-nucleotide polymorphisms (SNPs) identified for transcribed human sequences, as well as methods of using the nucleic acids. The polymorphisms are arranged in the order: 422 nucleotide sequences for SNPs that are silent; 58 nucleotide sequences for SNPs that lead to conservative amino acid changes; 139 nucleotide changes for SNPs that lead to nonconservative amino acid changes; and 32 nucleotide sequences for SNPs that involve a gap. In particular, the polymorphisms are related to angiopoietin, 4-hydroxybutyrate dehydrogenase, ATP-dependent RNA helicase, MHC Class I histocompatibility antigen, or phosphoglycerate kinase.

IC ICM C12Q001-68

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 13

IT 56-86-0, L-Glutamic acid, biological studies 345315-18-6 345315-19-7
 345315-20-0 345315-21-1 345315-22-2 345315-23-3 345315-24-4
 345315-25-5 345315-26-6 345315-27-7 345315-28-8 345315-29-9
 345315-30-2 345315-31-3 345315-32-4 345315-33-5 345315-34-6
 345315-35-7 345315-36-8 345315-37-9 345315-38-0 345315-39-1
 345315-40-4 345315-41-5 345315-42-6 345315-43-7 345315-44-8
 345315-45-9 345315-46-0 345315-47-1 345315-48-2 345315-49-3
 345315-50-6 345315-51-7 345315-52-8 345315-53-9 345315-54-0
 345315-55-1 345315-56-2 345315-57-3 345315-58-4 345315-59-5
 345315-60-8 345315-61-9 345315-62-0 345315-63-1 345315-64-2
 345315-65-3 345315-66-4 345315-67-5 345315-68-6 345315-69-7
 345315-70-0 345315-71-1 345315-72-2 345315-73-3 345315-74-4
 345315-75-5 345315-76-6 345315-77-7 345315-78-8 345315-79-9
 345315-80-2 345315-81-3 345315-82-4 345315-83-5 345315-84-6
 345315-85-7 345315-86-8 345315-87-9 345315-88-0 345315-89-1
 345315-90-4 345315-91-5 345315-92-6 345315-93-7 345315-94-8
 345315-95-9 345315-96-0 345315-97-1 345315-98-2 345315-99-3
 345316-00-9 345316-01-0 345316-02-1 345316-03-2 345316-04-3
 345316-05-4 345316-06-5 345316-07-6 345316-08-7
 345316-09-8 345316-10-1 345316-11-2 345316-12-3 345316-13-4
 345316-14-5 345316-15-6 345316-16-7 345316-17-8 345316-18-9
 345316-19-0 345316-20-3 345316-21-4 345316-22-5 345316-23-6
 345316-24-7 345316-25-8 345316-26-9 345316-27-0 345316-28-1
 345316-29-2 345316-30-5 345316-31-6 345316-32-7 345316-33-8
 345316-34-9 345316-35-0 345316-36-1 345316-37-2 345316-38-3
 345316-39-4 345316-40-7 345316-41-8 345316-42-9 345316-43-0
 345316-44-1 345316-45-2 345316-46-3 345316-47-4 345316-48-5
 345316-49-6 345316-50-9 345316-51-0 345316-52-1 345316-53-2
 345316-54-3 345899-36-7

RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); OCCU (Occurrence); USES (Uses)

(SNP involving nonconservative amino acid change; nucleic acids contg. single nucleotide polymorphisms in the human genome)

L4 ANSWER 19 OF 24 HCPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:435103 HCPLUS
 DOCUMENT NUMBER: 135:40998

TITLE: Complementary peptide ligands generated from the human genome
 INVENTOR(S): Roberts, Gareth Wyn; Heal, Jonathan Richard
 PATENT ASSIGNEE(S): Proteom Limited, UK
 SOURCE: PCT Int. Appl., 645 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001042277	A2	20010614	WO 2000-GB4776	20001213
WO 2001042277	A3	20020221		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1237907	A2	20020911	EP 2000-985549	20001213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			GB 1999-29464	A 19991213
			WO 2000-GB4776	W 20001213

AB The invention relates to the identification of complementary peptides from the anal. of protein and nucleotide sequence databases from the human genome. These specific complementary peptides interact with their relevant target proteins encoded in the human genome. Specific complementary peptides to the proteins encoded in the human genome can be used as reagents and drugs from drug discovery programs and as lead ligands to facilitate drug design and development.

IC ICM C07K007-00

CC 1-1 (Pharmacology)

IT	344841-95-8	344841-96-9	344841-97-0	344841-98-1	344841-99-2
	344842-00-8	344842-01-9	344842-02-0	344842-03-1	344842-04-2
	344842-05-3	344842-06-4	344842-07-5	344842-08-6	344842-09-7
	344842-10-0	344842-11-1	344842-12-2	344842-13-3	344842-14-4
	344842-15-5	344842-16-6	344842-17-7	344842-18-8	344842-19-9
	344842-20-2	344842-21-3	344842-22-4	344842-23-5	344842-24-6
	344842-25-7	344842-26-8	344842-27-9	344842-28-0	344842-29-1
	344842-30-4	344842-31-5	344842-32-6	344842-33-7	344842-34-8
	344842-35-9	344842-36-0	344842-37-1	344842-38-2	344842-39-3
	344842-40-6	344842-41-7	344842-42-8	344842-43-9	344842-44-0
	344842-45-1	344842-46-2	344842-47-3	344842-48-4	344842-49-5
	344842-50-8	344842-51-9	344842-52-0	344842-53-1	344842-54-2
	344842-55-3	344842-56-4	344842-57-5	344842-58-6	
	344842-59-7	344842-60-0	344842-61-1	344842-62-2	
	344842-63-3	344842-64-4	344842-65-5	344842-66-6	344842-67-7
	344842-68-8	344842-69-9	344842-70-2	344842-71-3	344842-72-4
	344842-73-5	344842-74-6	344842-75-7	344842-76-8	344842-77-9
	344842-78-0	344842-79-1	344842-80-4	344842-81-5	344842-82-6
	344842-83-7	344842-84-8	344842-85-9	344842-86-0	344842-87-1
	344842-88-2	344842-89-3	344842-90-6	344842-91-7	344842-92-8
	344842-93-9	344842-94-0	344842-95-1	344842-96-2	344842-97-3
	344842-98-4	344842-99-5	344843-00-1	344843-01-2	344843-02-3

344843-03-4	344843-04-5	344843-05-6	344843-06-7	344843-07-8
344843-08-9	344843-09-0	344843-10-3	344843-11-4	344843-12-5
344843-13-6	344843-14-7	344843-15-8	344843-16-9	344843-17-0
344843-18-1	344843-19-2	344843-20-5	344843-21-6	344843-22-7
344843-23-8	344843-24-9	344843-25-0	344843-26-1	344843-27-2
344843-28-3	344843-29-4	344843-30-7	344843-31-8	344843-32-9
344843-33-0	344843-34-1	344843-35-2	344843-36-3	344843-37-4
344843-38-5	344843-39-6	344843-40-9	344843-41-0	344843-42-1
344843-43-2	344843-44-3	344843-45-4	344843-46-5	344843-47-6
344843-48-7	344843-49-8	344843-50-1	344843-51-2	344843-52-3
344843-53-4	344843-54-5	344843-55-6	344843-56-7	344843-57-8
344843-58-9	344843-59-0	344843-60-3	344843-61-4	344843-62-5
344843-63-6	344843-64-7	344843-65-8	344843-66-9	344843-67-0
344843-68-1	344843-69-2	344843-70-5	344843-71-6	344843-72-7
344843-73-8	344843-74-9	344843-75-0	344843-76-1	344843-77-2
344843-78-3	344843-79-4	344843-80-7	344843-81-8	344843-82-9
344843-83-0	344843-84-1	344843-85-2	344843-86-3	344843-87-4
344843-88-5	344843-89-6	344843-90-9	344843-91-0	344843-92-1
344843-93-2	344843-94-3	344843-95-4	344843-96-5	344843-97-6
344843-98-7	344843-99-8	344844-00-4	344844-01-5	344844-02-6
344844-03-7	344844-04-8	344844-05-9	344844-06-0	344844-07-1
344844-08-2	344844-09-3	344844-10-6	344844-11-7	344844-12-8
344844-13-9	344844-14-0	344844-15-1	344844-16-2	344844-17-3
344844-18-4	344844-19-5	344844-20-8	344844-21-9	344844-22-0
344844-23-1	344844-24-2	344844-25-3	344844-26-4	344844-27-5
344844-28-6	344844-29-7	344844-30-0	344844-31-1	344844-32-2
344844-33-3	344844-34-4			

RL: PRP (Properties)

(unclaimed sequence; complementary peptide ligands generated from the human genome)

L4 ANSWER 20 OF 24 HCAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:707187 HCAPLUS
 DOCUMENT NUMBER: 133:262326
 TITLE: Cloning and cDNA and deduced amino acid sequences of 47 human secreted proteins
 INVENTOR(S): Rosen, Craig A.; Ruben, Steven M.; Komatsoulis, George
 PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA
 SOURCE: PCT Int. Appl., 387 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000058335	A1	20001005	WO 2000-US7534	20000322
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1165591	A1	20020102	EP 2000-916590	20000322
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

JP 2002539815 T2 20021126 JP 2000-608035 20000322
 PRIORITY APPLN. INFO.: US 1999-126598P P 19990326
 US 1999-171504P P 19991222
 WO 2000-US7534 W 20000322

AB The present invention relates to 47 novel human secreted proteins and isolated nucleic acids contg. the coding regions of the genes encoding such proteins. Tissue distribution, sequence homologies, and preferred epitope sites are provided for the secreted proteins, as well as chromosomal mapping of some of the genes. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins in bacterial, insect, and mammalian cells. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins. High-throughput screening assays are also provided for various putative activities of the secreted proteins.

IC ICM C07H021-04
 ICS C07K014-00; C07K016-00; C12N015-00; C12N015-63; C12N015-85;
 C12N015-86; C12Q001-68; G01N033-53

CC 3-3 (Biochemical Genetics)

Section cross-reference(s): 6, 13, 63

IT 295789-24-1P	295789-25-2P	295789-26-3P	295789-27-4P	
295789-28-5P	295789-29-6P	295789-30-9P	295789-31-0P	295789-32-1P
295789-33-2P	295789-34-3P	295789-35-4P	295789-36-5P	295789-37-6P
295789-38-7P	295789-39-8P	295789-40-1P	295789-41-2P	295789-42-3P
295789-43-4P	295789-44-5P	295789-45-6P	295825-50-2P	295825-51-3P
295825-52-4P	295825-53-5P	296252-00-1P	296252-01-2P	296252-02-3P
296252-03-4P	296267-70-4P	296267-72-6P	296267-73-7P	296267-74-8P
296267-75-9P	296267-81-7P	296267-82-8P	296267-83-9P	296267-84-0P
296267-85-1P	296267-91-9P	296267-92-0P	296267-93-1P	296267-96-4P
296267-97-5P	296267-98-6P			

RL: BOC (Biological occurrence); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation); USES (Uses)

(amino acid sequence; cloning and cDNA and deduced amino acid sequences of 47 human secreted proteins)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 24 HCPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2000:384238 HCPLUS
 DOCUMENT NUMBER: 133:29602
 TITLE: Allo and auto-reactive T-cell epitopes
 INVENTOR(S): Urbaniak, Stanislaw Joseph; Barker, Robert Norman
 PATENT ASSIGNEE(S): Aberdeen University, UK; The Common Services Agency for the Scottish Health Service
 SOURCE: PCT Int. Appl., 92 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000032632	A2	20000608	WO 1999-GB4027	19991201
WO 2000032632	A3	20000831		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,				

MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI,
 SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

EP 1135414 A2 20010926 EP 1999-973039 19991201

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: GB 1998-26378 A 19981201
 WO 1999-GB4027 W 19991201

AB The present invention relates to a pharmaceutical compn... for the prevention of alloimmunization of a subject or the immunosuppression of a response elicited by alloimmunization of a subject or an autoimmune hemolytic disease for said compn. comprising an immunol. effective epitope of a rhesus protein or an immunol. active analog or deriv. thereof.

IC ICM C07K014-705

ICS A61K038-17; A61P037-02; G01N033-569; G01N033-68

CC 15-2 (Immunochemistry)

Section cross-reference(s): 63

IT 122630-93-7	138777-28-3	197582-62-0	197582-64-2	197582-66-4
197582-68-6	197582-70-0	197582-74-4	197582-76-6	197582-78-8
197582-80-2	197582-81-3	197582-82-4	197582-83-5	
197582-84-6	197582-85-7	197582-86-8	197582-87-9	197582-88-0
197582-90-4	197582-91-5	197582-92-6	197582-93-7	197582-94-8
197582-95-9	197582-96-0	197582-97-1	197582-98-2	197582-99-3
197583-00-9	197583-01-0	197583-02-1	197583-04-3	197583-05-4
197583-06-5	197583-07-6	197583-08-7	197583-09-8	197583-10-1
197583-11-2	197583-12-3	197583-13-4	197583-14-5	197583-15-6
197583-16-7	273407-39-9	273407-40-2	273407-41-3	273407-42-4
273407-43-5	273407-44-6	273407-45-7	273407-46-8	273407-47-9
273407-48-0	273407-49-1	273407-50-4	273407-51-5	273407-52-6
273407-53-7	273407-54-8	273407-55-9	273407-56-0	273407-57-1
273407-58-2	273407-59-3	273407-60-6	273407-61-7	273407-62-8
273407-63-9	273407-64-0	273407-65-1	273407-66-2	273407-67-3
273407-68-4	273407-69-5	273407-70-8	273407-71-9	273407-72-0
273407-73-1	273407-74-2	273407-75-3	273407-76-4	273407-77-5
273407-78-6	273407-79-7	273407-80-0	273407-81-1	273407-82-2
273407-83-3	273407-84-4	273407-85-5	273407-86-6	273407-87-7
273407-88-8	273407-89-9	273407-90-2	273407-91-3	273407-92-4
273407-93-5	273407-94-6	273407-95-7	273407-96-8	273407-97-9
273407-98-0	273407-99-1	273408-00-7	273408-01-8	273408-02-9
273408-03-0	273408-04-1	273408-05-2	273408-06-3	273408-07-4
273408-08-5	273408-09-6	273408-10-9	273408-11-0	273408-12-1
273408-13-2	273408-14-3	273408-15-4	273408-16-5	273408-17-6
273408-18-7	273408-19-8	273408-20-1	273408-21-2	273408-22-3
273408-23-4	273408-24-5	273408-25-6	273408-28-9	273408-29-0
273408-30-3	273408-31-4	273408-32-5	273408-33-6	273408-34-7
273408-35-8	273408-36-9	273408-37-0	273408-38-1	273408-39-2
273408-40-5	273408-41-6	273408-42-7		

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(allo- and auto-reactive T-cell epitopes of rhesus protein for prevention of autoimmune hemolytic disease or immunosuppression elicited by alloimmunization)

L4 ANSWER 22 OF 24 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:633516 HCAPLUS

DOCUMENT NUMBER: 127:317984

TITLE: Identification of T-cell epitopes on the rhesus

AUTHOR(S): polypeptides in autoimmune hemolytic anemia
 Barker, Robert N.; Hall, Andrew M.; Standen, Graham R.; Jones, Jeff; Elson, Christopher J.
 CORPORATE SOURCE: Dep. Med. Therapeutics, Univ. Aberdeen, Aberdeen, UK
 SOURCE: Blood (1997), 90(7), 2701-2715
 CODEN: BLOOAW; ISSN: 0006-4971
 PUBLISHER: Saunders
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB We have shown previously that the Rhesus (Rh) polypeptides are the commonest targets for pathogenic anti-red blood cell (RBC) autoantibodies in patients with autoimmune hemolytic anemia (AIHA). The aim of the current work was to determine whether activated T cells from such patients also mount recall responses to epitopes on these proteins. Two panels of overlapping 15-mer peptides, corresponding to the sequences of the 30 kDa Rh proteins assocd. with expression of the D and Cc/Ee blood group antigens, were synthesized and screened for the ability to stimulate the in vitro proliferation of mononuclear cells from the peripheral blood or spleen of nine AIHA cases. Culture conditions were chosen that favor recall proliferation by previously activated T cells, rather than primary responses. In seven of the patients, including all four cases with autoantibody to the Rh proteins, two or more peptides elicited proliferation, but cells from eight of nine patients with other anemias and seven of nine healthy donors failed to respond to the panels. Multiple peptides were also stimulatory in two pos. control donors who had been alloimmunized with Rh-D-pos. RBCs. Six different profiles of peptides elicited response in the AIHA patients, and this variation may reflect the different HLA types in the group. Stimulatory peptides were identified throughout domains shared between, or specific to, each of the related 30 kDa Rh proteins, but T cells that responded to nonconserved regions did not cross-react with the alternative sequences. Anti-major histocompatibility complex class II antibodies blocked the response and depletion expts. confirmed that the proliferating mononuclear cells were T cells. Notably, splenic T cells that proliferated against multiple Rh peptides also responded to intact RBCs. We propose that pathogenic autoantibody prodn. in many cases of AIHA is driven by the activation of T-helper cells specific for previously cryptic on the Rh proteins.

CC 15-8 (Immunochemistry)
 IT 197582-62-0 197582-64-2 197582-66-4 197582-68-6 197582-70-0
 197582-72-2 197582-74-4 197582-76-6 197582-78-8 197582-80-2
 197582-81-3 197582-82-4 197582-83-5 197582-84-6 197582-85-7
 197582-86-8 197582-87-9 197582-88-0 197582-89-1 197582-90-4
 197582-91-5 197582-92-6 197582-93-7 197582-94-8 197582-95-9
 197582-96-0 197582-97-1 197582-98-2 197582-99-3 197583-00-9
 197583-01-0 197583-02-1 197583-04-3 197583-05-4 197583-06-5
 197583-07-6 197583-08-7 197583-09-8 197583-10-1 197583-11-2
 197583-12-3 197583-13-4 197583-14-5 197583-15-6 197583-16-7
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)
 (identification of T-cell epitopes on rhesus polypeptides in autoimmune hemolytic anemia)

L4 ANSWER 23 OF 24 HCPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1994:595904 HCPLUS
 DOCUMENT NUMBER: 121:195904
 TITLE: Analogs of humanized antibodies to tumor antigens and their use as neoplasm inhibitors
 INVENTOR(S): Do Couto, Fernando J. R.; Ceriani, Roberto L.; Peterson, Jerry A.; Padlan, Eduardo A.
 PATENT ASSIGNEE(S): Cancer Research Fund of Contra Costa, USA

SOURCE: PCT Int. Appl., 109 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9411509	A2	19940526	WO 1993-US11445	19931116
WO 9411509	A3	19940707		
W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5792852	A	19980811	US 1992-977696	19921116
US 5804187	A	19980908	US 1993-129930	19930930
US 6281335	B1	20010828	US 1993-134346	19931008
AU 9463964	A1	19940608	AU 1994-63964	19931116
CA 2173324	AA	19950420	CA 1993-2173324	19931116
WO 9510776	A1	19950420	WO 1993-US11444	19931116
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9458692	A1	19950504	AU 1994-58692	19931116
EP 674710	A1	19951004	EP 1994-903300	19931116
R: DE, ES, FR, GB, IE, IT, NL, SE				
EP 723663	A1	19960731	EP 1994-904804	19931116
R: DE, FR, GB, IT				
JP 09503663	T2	19970415	JP 1993-510496	19931116
JP 09503901	T2	19970422	JP 1993-512520	19931116
PRIORITY APPLN. INFO.:			US 1992-977696	A 19921116
			US 1993-129930	A 19930930
			US 1993-134346	A 19931008
			WO 1993-US11444	W 19931116
			WO 1993-US11445	W 19931116

- AB Analogs of humanized antibodies to tumor antigens with 1-3 complementarity detg. regions per chain are described for use in the diagnosis and treatment of tumors. The polypeptide may be conjugated with an effector agent, e.g. a neoplasm inhibitor, and be glycosylated. These analogs are used in diagnostic kits for neoplasms such as carcinomas and methods for in vivo imaging and treating a primary or metastasized neoplasm such as a carcinoma, and in vitro diagnosis of neoplasm, and ex vivo purging of neoplastic cells from a biol. fluid. These analogs may be manufd. by expression of the corresponding cloned genes; computer modeling of antibody surfaces is used to minimize the no. of changes involved in humanization. Polyclonal or monoclonal anti-idiotypic antibodies, optionally in combination with other effectors may be used in vaccines against cancer (no data). A mouse monoclonal antibody to an epitope of human milk fat globules and breast mucin was used in the prepn. of a humanized antibody. The binding of the humanized antibody to the epitope was comparable to that of the original mouse antibody.
- IC ICM C12N015-13
 ICS C07K015-28; G01N033-574; C12N015-62; A61K039-395; C12P021-08
- CC 1-6 (Pharmacology)
 Section cross-reference(s): 3, 9, 15
- IT 145061-00-3, Humanized antibody Br-E3 to human milk fat globule analog heavy chain variable region fragment (mouse human clone 152)
 150907-18-9, Humanized antibody KC4 to human breast epithelial mucin light chain variable region fragment (mouse human) 155547-57-2, Humanized antibody KC4 to human breast epithelial mucin heavy chain variable region

fragment (mouse human) 157079-80-6, Humanized antibody KC4 to human breast epithelial mucin light chain variable region fragment (mouse human)
157079-81-7, Humanized antibody KC4 to human breast epithelial mucin light chain variable region fragment (mouse human) 157079-82-8, Humanized antibody KC4 to human breast epithelial mucin light chain variable region fragment (mouse human) 157079-83-9, Humanized antibody KC4 to human breast epithelial mucin light chain variable region fragment (mouse human) 157079-84-0, Humanized antibody Br-E3 to human milk fat globule analog light chain variable region fragment (mouse human clone 152)
157079-85-1, Humanized antibody KC4 to human breast epithelial mucin heavy chain variable region fragment (mouse human) 157079-86-2, Humanized antibody KC4 to human breast epithelial mucin heavy chain variable region fragment (mouse human) 157079-87-3, Humanized antibody KC4 to human breast epithelial mucin heavy chain variable region fragment (mouse human) 157079-89-5, Humanized antibody KC4 to human breast epithelial mucin heavy chain variable region fragment (mouse human) 157108-30-0, Humanized antibody KC4 to human breast epithelial mucin light chain variable region fragment (mouse human) 157242-85-8, Humanized antibody KC4 to human breast epithelial mucin heavy chain variable region fragment (mouse human) 157414-45-4, Humanized antibody KC4 to human breast epithelial mucin heavy chain variable region fragment (mouse human) 157414-63-6,
Humanized antibody Br-E3 to human milk fat globule analog light chain variable region fragment (mouse human clone 152) 157414-64-7, Humanized antibody Br-E3 to human milk fat globule analog light chain variable region fragment (mouse human clone 152) 157414-65-8, Humanized antibody Br-E3 to human milk fat globule analog light chain variable region fragment (mouse human clone 152) 157414-66-9, Humanized antibody Br-E3 to human milk fat globule analog light chain variable region fragment (mouse human clone 152) 157414-67-0, Humanized antibody Br-E3 to human milk fat globule analog light chain variable region fragment (mouse human clone 152) 157414-68-1, Humanized antibody Br-E3 to human milk fat globule analog light chain variable region fragment (mouse human clone 152) 157414-69-2, Humanized antibody Br-E3 to human milk fat globule analog light chain variable region fragment (mouse human clone 152) 157414-70-5, Humanized antibody Br-E3 to human milk fat globule analog heavy chain variable region fragment (mouse human clone 152)
157414-71-6, Humanized antibody Br-E3 to human milk fat globule analog heavy chain variable region fragment (mouse human clone 152)
157414-72-7, Humanized antibody Br-E3 to human milk fat globule analog heavy chain variable region fragment (mouse human clone 152)
157414-73-8, Humanized antibody Br-E3 to human milk fat globule analog heavy chain variable region fragment (mouse human clone 152)
157414-74-9, Humanized antibody Br-E3 to human milk fat globule analog heavy chain variable region fragment (mouse human clone 152)
157414-75-0, Humanized antibody Br-E3 to human milk fat globule analog heavy chain variable region fragment (mouse human clone 152)
157414-76-1, Humanized antibody KC4 to human breast epithelial mucin light chain variable region fragment (mouse human) 157414-77-2, Humanized antibody KC4 to human breast epithelial mucin heavy chain variable region fragment (mouse human) 157481-47-5, Humanized antibody Br-E3 to human milk fat globule analog heavy chain variable region fragment (mouse human clone 152) 157906-39-3, Humanized antibody KC4 to human breast epithelial mucin light chain variable region analog (mouse human)
157906-40-6, Humanized antibody KC4 to human breast epithelial mucin heavy chain variable region analog (mouse human).
RL: PRP (Properties)
(amino acid sequence of)

DOCUMENT NUMBER: 94:119279
TITLE: Functional and nonfunctional joining in immunoglobulin light chain genes of a mouse myeloma
AUTHOR(S): Altenburger, Werner; Steinmetz, Michael; Zachau, Hans G.

CORPORATE SOURCE: Inst. Physiol. Chem., Univ. Muenchen, Munich, Fed. Rep. Ger.

SOURCE: Nature (London, United Kingdom) (1980), 287(5783), 603-7

CODEN: NATUAS; ISSN: 0028-0836

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Nucleotide sequences were detd. for leader, variable (V), and joining (J) gene segments, and adjacent regions of 2 rearranged alleles of the same kappa-chain producing mouse myeloma, comprising apprx. 3200 base pairs. Sequence comparisons are reported. V-J joining in one of the alleles led to a reading frame with a stop codon within the J-gene segment. Allelic exclusion was apparently realized in this tumor through the formation of such a nonfunctional allele.

CC 15-13 (Immunochemistry)

IT 76520-45-1 76877-08-2 76877-09-3 76881-42-0

RL: BIOL (Biological study)

(mouse myeloma Ig light chain fragment)